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7Abstract
Orexins (orexin-A and -B) are neuropeptides with multiple physiological functions,
among which regulation of wakefulness and appetite are the best known. Neurons
producing orexins are localized in the lateral hypothalamus, from where they send
projections to many parts of the brain. Orexins exert their functions by activating two
G-protein-coupled receptors, OX1 and  OX2. Orexin receptor expression was first
reported in the brain, but they are also expressed outside of the central nervous system
(CNS). Upon activation, OX1 and  OX2 receptors can couple to heterotrimeric G-
proteins of different families, including Gq, Gs and Gi/o. Orexin receptor activation can
evoke increases in intracellular Ca2+ concentrations via multiple mechanisms,
including activation of phospholipase C and increased Ca2+ influx, and it also
regulates adenylyl cyclase activity, both positively and negatively. Multiple kinases
have also been reported in their signaling cascades, including protein kinases C and
D, extracellular signal-regulated kinase, p38, Src, and phosphatidylinositol-3-kinase.
Previous studies have suggested interactions between the orexin and
endocannabinoid systems. The endocannabinoid system consists of
endocannabinoids, which are neuromodulatory lipids produced on demand by
neurons, their effectors (CB1 and  CB2 cannabinoid receptors, as well as other
receptors and channels), and finally the enzymes that degrade them. The cannabinoid
and  orexin  systems  have  several  overlapping  functions,  such  as  regulation  of  pain
transmission, appetite, learning, and reward. Evidence for the existence of interactions
between these systems has been gained from physiological, but also molecular
studies. Even heteromerization of CB1 and OX1 receptors has been reported.
In this thesis, the signaling of the OX1 receptor was further investigated, with
special emphasis on lipid mediators. Recombinant cells (mainly CHO cells) were
employed as model systems. We were able to directly demonstrate the activation of
phospholipase D upon OX1 stimulation, and consequently add PLD to the signaling
cascades mediating orexin responses. Phospholipase D activation was mediated by a
novel  protein  kinase  C  isoform,  most  likely  protein  kinase  Cδ.  OX1 receptor
activation also leads to the release of two other messengers: arachidonic acid and the
endocannabinoid 2-arachidonoylglycerol. In this thesis, the release of these
messengers and the pathways leading to their production, upon orexin receptor
activation, were investigated in detail for the first time. Powerful arachidonic acid
release by cytosolic phospholipase A2 (cPLA2) was observed in recombinant CHO
cells. In contrast, 2-arachidonoylglycerol was released by a cascade involving
activation of phospholipase C and diacyglycerol lipase; this was observed in CHO,
neuro-2a, and HEK293 cells. By utilizing CHO cells in an artificial cell-cell
communication assay, we saw that the released 2-arachidonoylglycerol can act as a
paracrine messenger, activating neighboring cells expressing CB1 cannabinoid
receptors. 2-Arachidonoylglycerol similarly also acted as an autocrine messenger, and
co-signaling of OX1 and  CB1 receptors upon orexin stimulation of the receptor-co-
expressing cells via the "2-arachidonoylglycerol loop" led to the potentiation of ERK
8activation. This implies that the significance of the previously reported OX1-CB1
interaction is more likely to originate from functional than physical interaction of the
receptors. However, the idea of heteromerization between OX1 and CB1 receptors is
interesting,  and  in  the  final  study  of  the  present  series,  we  utilized  the
bioluminescence resonance energy transfer (BRET) method to investigate constitutive
homo- and heteromerization between OX1, OX2, and CB1 receptors. According to our
results, all receptor combinations readily form heteromeric complexes when
expressed in CHO cells.
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1. Introduction
Cells are able to communicate with each other by various means. This communication
is  referred  to  as  signaling,  and  it  is  fundamental  to  the  function  of  cells  and  tissues.
These signals can be relayed by different transmitters, for example nucleotides, lipids,
amino acid derivatives, biogenic amines, or polypeptides, which cells secrete and
which then relay the signal to the same cells that secrete them (autocrine signaling),
neighboring cells (paracrine signaling), or cells that can be far from the producing
cells, in which case the signaling molecules reach their target by being carried in
blood or hemolymph (endocrine signaling).
When these signaling molecules reach their targets, they bind to their
receptors, which can be on the cell membrane or inside the cells (nuclear receptors).
Molecules that bind to certain receptors and activate them are called agonists, while
receptor inhibitors are called antagonists. Receptor activation leads to the activation of
different signaling cascades inside the cell. This is called intracellular signaling.
The cell membrane receptors can be divided into three major groups based on
their structure and function. Ionotropic receptors are protein complexes that function
as ion channels, opening upon agonist binding. Enzyme receptors, on the other hand,
are receptors that, from the cytosolic side, act as enzymes once activated. The third
class of cell membrane receptors is G-protein-coupled receptors (GPCRs).
GPCRs are the largest family of cell membrane receptors, and they are a target
for about 40 % of all currently used pharmaceuticals. Therefore, understanding the
biology of these receptors and the signaling cascades they activate is fundamental for
the discovery and development of new therapeutic drugs.
Orexin receptors are GPCRs activated by the neuropeptides orexin-A and -B.
They participate in the regulation of several physiological functions including
wakefulness, appetite, pain and addiction.  The lack of orexin signaling causes
narcolepsy with cataplexy, a disorder where a patient falls asleep at inappropriate
times and loses muscle control. Because orexins are so central for the regulation of
wakefulness, they are seen to have potential for development of treatments for sleep-
related problems.
The intracellular signaling pathways activated by orexin receptors are very
diverse. This thesis concentrates on expanding our knowledge of those signaling
pathways. The interactions of orexin receptors with cannabinoid receptors (another
GPCR subfamily with many physiological functions) are also investigated.
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2. Review of the Literature
2.1 G-protein-coupled receptors and their main effectors
2.1.1 G-protein-coupled receptors
G-protein-coupled receptors (GPCRs) constitute the largest family of cell membrane
receptors, with over 800 genes in the human genome (reviewed in Civelli et al.,
2013). They are a heterogeneous group of receptors, divided into five families
according to the phylogenetic GRAFS classification system: Glutamate, Rhodopsin,
Adhesion, Frizzled, and Secretin (Schioth and Fredriksson, 2005). GPCRs are also
very interesting from the point of view of the pharmaceutical industry, and about 40%
of existing therapeutic drugs act through targeting GPCRs (reviewed in Lin, 2013).
The  GPCRs  respond  to  a  huge  variety  of  stimuli,  ranging  from  messengers
secreted by cells (e.g. lipids, biogenic amines, polypeptides, amino acids) to external
stimuli such as photons or organic compounds, acting as olfactants or pheromones
(reviewed in Kobilka, 2007). Despite the variability of their ligands, they all share
certain structural features. GPCRs have 7 transmembrane domains of α-helical
conformation, spanning the plasma membrane, connected by 3 intracellular and 3
extracellular loop regions. The N-terminus is extracellular and the C-terminus is
intracellular. The binding site for ligands varies according to the type of ligand, but
the N-terminal parts and transmembrane regions of the receptors have been shown to
be important for ligand binding (reviewed in Kobilka, 2007).
2.1.2 Heterotrimeric G-proteins
Upon activation, GPCRs interact with intracellular heterotrimeric G-proteins (Figure
1). These G-proteins are GTPases, which are formed of three subunits: α, β, and γ.
The classical scheme of signal transduction is that when the heterotrimeric G-protein
interacts with the activated GPCR, it releases GDP, making the nucleotide-binding
site available for GTP. The GPCR thus acts as a guanine nucleotide exchange factor
(GEF)  for  the  G-protein.  The  GTP binding  site  is  in  the  α-subunit  of  the  G-protein,
and  when  GTP  is  bound,  the  βγ-complex  dissociates  from  the  α-subunit.  The  GTP-
bound α-subunit can then interact with and activate its targets. The βγ-subunit is then
also free to activate its target proteins, such as various ion channels and kinases
(Milligan and Kostenis, 2006). The inactivation of the Gα-subunit is regulated by a
group of proteins called regulators of G-protein signaling (RGS), which accelerate
GTP  hydrolysis.  After  GTP  hydrolysis  and  expulsion  of  the  phosphate,  the  Gα-
subunit returns to its inactive, GDP-bound state and reunites with the Gβγ-subunit,
and the cycle can start again (Hamm, 1998; Hewavitharana and Wedegaertner, 2012).
It is, however, noteworthy that this classical scheme of heterotrimeric G-protein
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dissociation has been challenged, and there is evidence that dissociation of Gα- and
Gβγ-subunits does not always occur (Rebois et al., 1997; Gales et al., 2006).
The effectors of dissociated G-protein subunits, as well as the nature of the
interaction (activation or inhibition), depend on the G-protein type. Heterotrimeric G-
proteins are divided into four subfamilies: Gs,  Gi/o,  Gq,  and  G12/13. This division is
according to their α-subunits (Gαs, Gαi/o, Gαq,  and Gα12/13), and the typical members
of these subfamilies have certain classical responses upon receptor activation: Gαs
activates adenylyl cyclase (AC), whereas Gαi inhibits it. Gαq, on the other hand,
activates phospholipase Cβ (PLCβ), and Gα12/13 is known to regulate many proteins,
of which RGS-RhoGEFs (RGS domain-containing Rho GEFs) are the best known
(Hewavitharana and Wedegaertner, 2012).
In addition to activating a variety of signaling cascades via G-proteins, GPCRs
can also activate signaling pathways independent of G-proteins. The best-known
proteins that interact with GPCRs are GPCR kinases and arrestins (reviewed in
Magalhaes et al., 2012). Through this ability to signal both via G-proteins and
independently of them, the signaling cascades activated by GPCRs become extremely
variable.
Figure 1. A classical scheme of activation of a heterotrimeric G-protein by a GPCR
upon agonist binding. GPCR, G-protein-coupled receptor; GDP, guanosine
diphosphate; GTP guanosine triphosphate.
Table 1. Main effectors for typical members of different heterotrimeric G-protein
families.
Heterotrimeric G-protein
families
Main effectors
Gαq/11 PLC ↑
Gαs AC ↑
Gαi/o AC ↓
Gα12/13 PLC and PLD ↑
AC, adenylyl cyclase; PLC, phospholipase C; PLD, phospholipase D. Arrows
pointing upwards represent increasing activity, whereas arrows pointing downwards
represent decreasing activity.
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2.1.3 Phospholipase C and Ca2+ signaling
Classically, coupling to Gq proteins  results  in  the  activation  of  phospholipase  Cβ
(PLCβ), which hydrolyzes phosphatidylinositols, especially phosphatidylinositol-4,5-
bisphosphate (PIP2). Hydrolyzation of PIP2 produces inositol-1,4,5-trisphosphate (IP3)
and diacylglycerol (DAG), both of which are important second messengers (reviewed
in Berridge, 2009; Yang et al., 2013b). IP3 activates IP3 receptors in the endoplasmic
reticulum (ER), which leads to the release of Ca2+ into  the  cytosol,  and  hence  an
increase in the cytoplasmic Ca2+ concentration  (Exton,  1996).  Depletion  of  ER Ca2+
stores is detected by stromal interaction molecule 1 (STIM1), which then leads to the
opening of Ca2+ release-activated Ca2+ (CRAC) channels, now known to consist of
Orai1 subunits (reviewed in Berridge, 2009; Fahrner et al., 2013).
Ca2+ is a fundamental second messenger. It regulates an array of functions,
from  the  secretion  of  transmitters  in  synapses  and  contraction  of  smooth  muscle  to
fertilization, proliferation, and cell metabolism. Because Ca2+ is involved in
controlling so many and so variable functions, it is considered one of the most
important second messengers (reviewed in Berridge, 2009).The importance of Ca2+ as
a signaling molecule is reflected in the wide range of channels and pumps that
regulate the intracellular Ca2+ concentration. The temporal and spatial dynamics of the
increase in Ca2+ determine the target regulation by Ca2+ (Bootman et al., 2001).
2.1.4 Adenylyl cyclases
Another classical second messenger is cAMP, which was actually the first
intracellular second messenger to be discovered (reviewed in Antoni, 2000). Levels of
cAMP in cells are regulated by adenylyl cyclases (ACs), which convert ATP to
cAMP. Cyclic nucleotide phosphodiesterases, on the other hand, hydrolyze cAMP to
AMP.  In  mammals,  there  are  nine  membrane-bound  AC  isoforms,  which  can  be
divided into four families based on their sequences (reviewed in Halls and Cooper,
2011). The classical pathway for AC activation is that a GPCR activates a Gs protein
and the Gαs subunit activates the effector, AC. Alternatively, if the GPCR couples to
Gi,  the  Gαi subunit inhibits AC activity (reviewed in Antoni, 2000). However, also
other factors regulate the activity of ACs. The intracellular Ca2+ concentration can
modulate AC activity: this can occur via the Ca2+–calmodulin complex, calcineurin,
Ca2+-calmodulin-activated kinase (CaMK), or protein kinase C (PKC). The end result
of the modulation (inhibition or activation) depends on the AC subtype (reviewed in
Halls and Cooper, 2011).
There are many targets for cAMP in cells. The most classical and well-
characterized target for cAMP is activation of the cAMP-dependent kinase, protein
kinase A (PKA). When cAMP levels in the cell increase, PKA is activated, its
catalytic subunit moves into the nucleus, and it activates by phosphorylation the
transcription factor cAMP-responsive element-binding protein (CREB).
Phosphorylated CREB regulates the expression of various genes, most of them related
to cell survival and growth (Mayr and Montminy, 2001). CREB is, however, only one
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of the many PKA targets. A-kinase anchoring proteins (AKAP) bind PKA, but also
other proteins, and scaffold its targets to multiprotein signaling complexes. New
AKAPs and their binding partners are continuously being discovered (reviewed in
Esseltine  and  Scott,  2013).  In  addition  to  PKA-mediated  pathways,  cAMP  also
directly  regulates  the  function  of  HCN  and  CNG  channels  and  exchange  proteins
directly  activated  by  cAMP  (EPACs),  which  act  as  GEFs  for  the  small  G-proteins
Rap1 and Rap2 (reviewed in Schmidt et al., 2013). Physiologically, cAMP is essential
for almost all functions imaginable, and cAMP signaling has been verified in
practically all tissues.
2.2 Orexins and orexin receptors
2.2.1 Orexins
In 1998, two groups independently reported novel neuropeptides found in the lateral
hypothalamus of the rat. One of the groups called these peptides hypocretin-1 and -2
(de Lecea et  al., 1998), while the other group called them orexin-A and -B and their
receptors OX1 and OX2 (Sakurai et al., 1998). These groups were, in fact, describing
the same peptides, and both names (hypocretins and orexins) are still in use. However,
the Nomenclature Committee of the International Union of Basic and Clinical
Pharmacology (IUPHAR) recommends the use of orexin nomenclature for the
peptides and receptors, and hypocretin for the genes (Gotter et al., 2012). Thus, the
peptides are prepro-orexin (PPO), orexin-A and orexin-B, and the receptors are OX1
and OX2 receptors, while the rodent genes encoding PPO and the receptors are Hcrt,
Hcrtr1 and Hcrtr2 (all capital letters for the corresponding human genes),
respectively. Both orexin-A (33 amino acids) and -B (28 amino acids) are cleaved and
modified from the precursor PPO (de Lecea et al., 1998; Sakurai et al., 1998; Figure
2). In mammals, the peptide sequences for orexin-A and -B are highly conserved:
orexin-A is identical in rats, mice, pigs, dogs, and humans, whereas in orexin-B, there
are only slight changes in one or two amino acids between these species (reviewed in
Kukkonen, 2013b). Orexins are also expressed and have been shown to function in
teleost fish (Alvarez and Sutcliffe, 2002; Kaslin et al., 2004; Yokobori et al., 2011).
The orexin system therefore seems to have evolved quite early in vertebrate evolution.
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Figure 2. Orexin-A and –B are both cleaved from prepro-orexin. Human prepro-
orexin amino acid sequence with orexin-A in red and orexin-B in blue.
2.2.2 Orexin receptors
Orexins act via OX1 and  OX2 orexin  receptors,  which  are  GPCRs  of  the  rhodopsin
family (Sakurai et al., 1998). According to the original study, the affinity of orexins
for  the  two  receptors  is  different:  OX2 receptor bound both orexin-A and -B with
equal affinity, whereas OX1 bound and was activated 10 times more potently by
orexin-A than by orexin-B (Sakurai et al., 1998). However, more recent findings have
questioned this (reviewed in Kukkonen, 2013b).
Orexin receptors and orexins were initially found in the hypothalamus (de
Lecea et al., 1998; Sakurai et al., 1998). The orexin-producing neurons have their cell
bodies in the lateral hypothalamus, from where they send projections to many regions
in the brain (Peyron et al.,  1998).  The  regions  of  the  brain  that  express  orexin
receptors are discussed in more detail in 2.4.1. It has subsequently been shown that
orexin receptors are also expressed in tissues outside of the central nervous system
(CNS), such as the gastrointestinal tract, white and brown adipose tissue, adrenal
gland, and pancreas (reviewed in Kukkonen, 2013b).
Orexin receptors were first reported to couple to Gq proteins (Sakurai et al.,
1998), but later it became clear that they actually also couple to Gs and Gi/o proteins
(Karteris et al., 2001; Bernard et  al., 2002; Karteris et al., 2005; reviewed in
Kukkonen and Leonard, 2013). In addition to coupling to G-proteins, orexin
receptors, like other GPCRs, are able to activate signaling cascades independent of G-
protein coupling (reviewed in Kukkonen and Leonard, 2013).
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2.3 Orexin receptor signaling
Orexin receptors activate versatile signaling cascades. A simplified overview of these
signaling cascades is presented in Figure 3.
Figure 3. A simplified scheme of signaling cascades regulated by OX1 orexin
receptors. AA, arachidonic acid; AC, adenylyl cyclase; 2-AG, 2-
arachidonoylglycerol; cAMP, cyclic adenosine monophosphate; CB1, cannabinoid
receptor 1; cPLA2, Ca2+-dependent/cytosolic phospholipase A2; DAG, diacylglycerol;
DAGK, diacylglycerol kinase; DAGL, diacylglycerol lipase; ERK, extracellular
signal-regulated kinase; Elk1, ETS domain containing protein; IP3, inositol
trisphosphate; IP3R, inositol trisphosphate receptor, MAGL, monoacylglycerol lipase;
MEK, extracellular signal-regulated kinase kinase; OX1, orexin receptor 1; PA,
phosphatidic acid; PAP, phosphatidic acid phosphohydrolaze; PKC, protein kinase C;
PLC, phospholipase C; PLD, phospholipase D; TRP, transient receptor potential
channel.
2.3.1 Ca2+ in orexin receptor signaling
Ca2+ signaling was among the first functional responses reported for orexin receptors
upon stimulation with orexin-A. When the orphan GPCR, GFAN72, was
deorphanized and named an orexin receptor, this was done by transfecting CHO cells
with the cDNA encoding this receptor, activating it with possible ligands, and
measuring  the  Ca2+ responses (Sakurai et al., 1998). Upon orexin stimulation, the
concentration of intracellular Ca2+ increases: this was suggested to be due to Gq
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coupling of orexin receptors (Sakurai et al., 1998). However, orexin receptor
activation-induced Ca2+ signaling is more complicated than this.
It has been shown that the increase in intracellular Ca2+ upon orexin receptor
activation is dependent on the extracellular Ca2+ concentration (Smart et  al., 1999;
Lund et al., 2000). Orexin receptors are thought to regulate receptor-operated calcium
channels (ROCs), which include non-selective cation channels [NSCCs, such as
transient receptor potential (TRP) channels] and the hyperpolarization-activated
(HCN) and cyclic-nucleotide-gated (CNG) channels (Yang and Ferguson, 2002, 2003;
Yang et al., 2003; Larsson et al., 2005; Li et al., 2010). Orexin receptor activation can
also lead to an increase in the intracellular Ca2+ concentration by the reverse-mode
action  of  the  Na+/Ca2+ exchanger (NCX) (Louhivuori et al., 2010). In neurons and
other excitable cells, orexin receptors also activate L- and N-type voltage-gated Ca2+
channels (Uramura et al., 2001; Kohlmeier et al., 2008; Xia et al., 2009; Wu et al.,
2013). The rise in the intracellular Ca2+ concentration is therefore dependent on many
different mechanisms, including ROCs, SOCs, and IP3-mediated Ca2+ release.
2.3.2 Adenylyl cyclases as effectors of orexin receptors
Orexin receptors have been shown to regulate AC activity (Malendowicz et al., 1999;
Mazzocchi et al., 2001; Randeva et al., 2001; Holmqvist et al., 2005; Karteris et al.,
2005; Tang et al., 2008). Both positive and negative regulation has been detected in
recombinant cells, and various signaling cascades activated by orexin receptors lead
to modulation of AC activity, including direct activation via Gαs, direct inhibition via
Gαi, and indirect and conditional activation via Gαq-mediated activation of the
PLC-PKC cascade (Holmqvist et  al., 2005). The physiological relevance of orexin
receptor-induced modulation of AC activity has mostly been studied in adrenocortical
cells, both in vitro and in vivo. Orexin receptor-induced AC–PKA activation has been
shown to regulate the secretion of corticosteroids from the adrenal gland
(Malendowicz et al., 1999; Mazzocchi et al., 2001).
2.3.3 Activation of protein kinases by orexin receptors
Orexin receptors utilize several kinases in their signaling. These kinases include
protein kinase C (PKC) (Uramura et al., 2001), extracellular signal-regulated kinase 1
and 2 (ERK1 and -2) (Milasta et al., 2005; Ammoun et al., 2006a), p38 (Ammoun et
al., 2006a; Sellayah et al., 2011), Src (Ammoun et al., 2006a; Voisin et al., 2008),
protein kinase D (PKD) (Peltonen et al., 2010), AMP-activated kinase (AMPK) (Wu
et al., 2013), and phosphoinositide-3-kinase (PI3K) (Ammoun et al., 2006a;
Skrzypski et al., 2011).
The kinases that orexin receptors are known to activate, differ according to the
cell type. Interestingly, orexin receptors activate kinases that are related to cell
survival, growth, proliferation, and motility, such as ERK and PI3K (Mendoza et al.,
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2011). On the other hand, orexin receptors are also known to activate p38, which is a
kinase known to mediate apoptosis, but which is also involved in cell cycle
progression (Thornton and Rincon, 2009). Orexin receptor-induced p38 activation has
been shown to cause apoptotic cell  death in CHO cells (Ammoun et al., 2006b), but
differentiation in other cell lines such as HIB1b preadipocytes, mesenchymal
C3H10T1/2 cells (Sellayah et al., 2011) and in human adrenal cell line H293R
(Ramanjaneya et  al., 2008; Ramanjaneya et  al., 2009). Orexins regulate synaptic
plasticity, possibly partially via kinase cascades (Selbach et al., 2004; Borgland et al.,
2006; Chen et al., 2008; Selbach et al., 2010; Yang et al., 2013a).
PKCs are serine/threonine kinases divided into three groups: classical (cPKC),
novel  (nPKC),  and  atypical  (aPKC).  These  PKC  subtypes  differ  from  each  other  in
their activation, and partially also in their substrates. Orexin receptors can activate at
least cPKCs and nPKCs. These subtypes are activated by DAG, which is an important
second messenger in orexin receptor signaling. Upon activation by orexin receptors,
PKCs are indicated to regulate, for example, NSCCs (Xia et al., 2009), L- and N-type
Ca2+ channels (Uramura et al., 2001), phospholipase D (Paper I), inwardly rectifying
K+ channels  (Nakajima  and  Nakajima,  2010),  ERK,  and  CREB  (Ammoun et al.,
2006a; Guo and Feng, 2012).
2.3.4 Lipid mediators in orexin receptor signaling
Phospholipases hydrolyze cell membrane glycerophospholipids. The
glycerophospholipid substrates and the cleavage sites where phospholipases act differ
between phospholipases, and a wide range of products is thus formed. Phospholipase-
produced lipid mediators are important for orexin receptor signaling (reviewed in:
Kukkonen, 2013a). Orexin receptors activate phospholipases C, A2 and D (Lund et
al., 2000; Johansson et al., 2007, 2008; Turunen et al., 2010; Paper I; Paper II).
Phospholipase C
 As mentioned in 2.2.2, orexin receptors couple to heterotrimeric Gq proteins, which
likely signal further to PLCβ. There are six subtypes of phospholipase C (PLC): β, γ,
δ, ε, ζ and  η,  and  all  of  these  subtypes  share  the  requirement  for  Ca2+ for their
activation (reviewed in Yang et al., 2013b). In addition to Gq coupling, orexin
receptor activation is capable of leading to a rise in the intracellular Ca2+
concentration, the activation of different kinases, including PI3K, and the activation
of small G-proteins of the Ras family. Through these pathways, orexin receptors
could  be  able  to  activate  all  subtypes  of  PLCs,  but  it  is  still  unclear  which  subtypes
are relevant for orexin receptor signaling (Johansson et al., 2007; reviewed in:
Kukkonen, 2013a). The PLC activity leads to production of DAG, which can be
further phosphorylated to phosphatidic acid (PA), both of which are important lipid
mediators with many targets.
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Phospholipase A2
The first discovered PLA2 was sPLA2, found in the venom of cobras and rattlesnakes.
Similar types of secreted enzymes were then found in the porcine pancreas (reviewed
in Dennis et al., 2011). In 1991, two groups also managed to clone (Clark et al., 1991)
and purify (Kramer et al., 1991) a Ca2+-dependent cytosolic PLA2 from human
monoblasts. Phospholipase A2 (PLA2) enzymes can be divided into secreted (sPLA2),
cytosolic (cPLA2), Ca2+-independent (iPLA2), and lipoprotein-associated (Lp-PLA2)
groups (reviewed in Dennis et al., 2011). All of these groups contain many members.
PLA2 enzymes hydrolyze different glycerophospholipids at the sn-2 position,
therefore releasing a free fatty acid. In most cases, the released fatty acid is
arachidonic acid (AA), a precursor for the synthesis of prostaglandins and
leukotrienes, among others, but also a signaling molecule by itself. Orexin receptor
activation leads to strong AA release by cPLA2 activation in recombinant CHO cells
(Turunen et al., 2010; Paper II).
Free AA can regulate the activity of different cation channels, for example the
highly Ca2+-selective AA-regulated channels (ARCs) (Mignen and Shuttleworth,
2000). These channels resemble CRAC channels, and are also composed of Orai1 and
3 subunits, but function independently of the depletion of internal Ca2+ stores. Like
CRACs, ARCs are also activated by STIM1, but the activation mechanism is
different. ARC activation, by receptor-induced AA generation, already occurs at low
(physiologically relevant) agonist concentrations and generates oscillatory Ca2+
signals (reviewed in Shuttleworth, 2009). AA also modulates the activity of many
other channels, such as various K+ and  Na+ channels,  L-  and  N-type  Ca2+ channels,
and TRP channels (reviewed in Meves, 2008). The effect of AA on these channels is
mainly inhibitory, while AA or its metabolites activate TRP channels, such as the
vanilloid TRPs, TRPV1, and TRPV4 (reviewed in Meves, 2008; Kukkonen, 2011).
Phospholipase D
Phospholipase  D1  and  D2  (PLD1  and  PLD2)  are  the  classical  mammalian  PLD
enzymes (reviewed in Jenkins and Frohman, 2005). There are also other PLDs that
are  structurally  different  from  the  classical  PLDs,  such  as  PLD3  and  NAPE-PLD
(Wang and Ueda, 2009; Osisami et al., 2012). Yet another different PLD enzyme is
mitoPLD, which, as its name implies, resides in mitochondrial membranes, where it
hydrolyzes cardiolipin to produce PA to stimulate mitochondrial fusion (reviewed in
Gao and Frohman, 2012). PLD1 and PLD2 utilize phosphatidylcholine (PC) as a
substrate to produce PA and free choline. They are regulated quite differently,
although they both require PIP2 for their activity. PLD1 is activated by various
factors, such as the tyrosine kinase Src, small G-proteins of Rho and Arf families, and
PKC, whereas PLD2 is constitutively active, and can be activated by Arf only in
special circumstances (reviewed in Frohman et al., 1999).
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Orexin receptors activate PLD1 via nPKC (likely PKCδ) (Paper I). This
activation is very powerful,  but it  has so far only been studied in CHO cells,  and its
physiological relevance thus remains to be shown. PA has dozens of different protein
targets, and therefore the variety of possible downstream signaling pathways is large
(Jang et al., 2012). PA activates many kinases, including phosphatidylinositol-4-
phosphate 5-kinase, which generates PIP2, mitogen-activated protein kinase kinase
kinase (MAPKKK) Raf1, and protein kinase Cζ. Some phosphatases and the small G-
proteins, Arf1 and Arf6, are also activated by PA. One of the most studied PA targets
is the mammalian target of rapamycin complex 1 (mTORC1). These targets of PA are
involved in the regulation of various cellular functions, such as growth, proliferation,
vesicle trafficking, endocytosis, exocytosis, cell migration, and the regulation of
apoptosis (reviewed in Jang et al., 2012). In addition, released PA can be easily
converted to other lipid mediators, i.e. to DAG by phosphatidic acid
phosphohydrolase (PAP) or to lyso-PA (LPA) by PA-PLA1 or PA-PLA2, which
further increases the complexity of the signaling network.
Endocannabinoid production
Endocannabinoids are lipid mediators that have various functions in the CNS, but also
in the peripheral tissues (reviewed in Fonseca et al., 2013). Their functions and
physiology are further discussed in section 2.5.
The endocannabinoid system includes the endocannabinoids, their
synthesizing enzymes, their receptors (CB1 and  CB2), and the enzymes that degrade
them. The best-characterized endocannabinoids are anandamide (Devane et al., 1992)
and 2-arachidonoylglycerol (2-AG) (Sugiura et al., 1995). Both molecules are
derivatives of AA, but their generation pathways are different. Anandamide is
released from N-arachidonoyl-phosphatidylethanolamine by an enzyme called NAPE-
PLD. 2-AG, on the other hand, is derived from PLC activation, which produces DAG.
This is then hydrolyzed by DAG lipase (DAGL) to 2-AG and a free fatty acid. There
are also alternative pathways for endocannabinoid production, but these are thought to
be of lesser importance. Endocannabinoids are degraded via different pathways.
Anandamide is hydrolyzed by fatty acid amide hydrolase (FAAH), and 2-AG is
hydrolyzed by monoacylglycerol lipase (MAGL). They can also be oxidized by
cyclooxygenases (COX) or lipoxygenases (LOX), which act on the arachidonate
moiety of endocannabinoids (reviewed in Fonseca et al., 2013).
One recently discovered lipid mediator for orexin receptor signaling is
2-AG (Haj-Dahmane and Shen, 2005; Ho et al., 2011; Turunen et al., 2012). Orexin
receptor activation leads to the release of 2-AG via the activation of PLC and DAGL.
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2.4 Orexin physiology
Orexins are involved in the regulation of several physiological functions, from the
best-known effects on appetite and sleep/wakefulness to roles in reward, stress and
pain modulation (Sakurai et al., 1998; Chemelli et al., 1999; Lin et al., 1999; Sutcliffe
and de Lecea, 1999; Ida et al., 2000b; Bingham et al., 2001; Harris et al., 2005). They
have also been shown to regulate plasma corticosterone levels, blood pressure, overall
metabolism, and the function and development of brown adipose tissue (BAT)
(Lubkin and Stricker-Krongrad, 1998; Malendowicz et al., 1999; Samson et al., 1999;
Sellayah et al., 2011; Tupone et  al., 2011). Orexins and their receptors were first
found in the hypothalamus (de Lecea et al., 1998; Sakurai et  al., 1998), but their
expression is not restricted there. Orexin receptors are also expressed outside the CNS
in various tissues, including the gastro-intestinal tract, pancreas, pituitary gland,
adrenal gland, the reproductive system of males, and brown and white adipose tissue
(reviewed in Kukkonen, 2013b; Leonard and Kukkonen, 2013). Functions of the
orexinergic system are often divided into functions within the CNS and in the
periphery. However, it is not always easy to make a distinction between the central
and peripheral functions.
2.4.1 Orexins and their receptors in the CNS
Orexin neurons refer to neurons that produce orexin peptides. Orexin neurons are
situated in the lateral hypothalamic area, from which they send projections to multiple
brain regions (Figure 4). Many of these are involved, for example, in maintaining
wakefulness, but regions involved in learning and memory, reward, and feeding also
receive projections from orexin neurons. The brain regions where orexin neurons send
projections have been investigated mostly in rats by immunostaining of the orexin-
containing neurons (Peyron et al., 1998; Nambu et al., 1999) and by determining the
expression of OX1 and OX2 mRNA in the target areas (Trivedi et al., 1998; Lu et al.,
2000; Zhang et al., 2011). These areas include the locus coerulaeus (LC), dorsal raphe
(DR), tuberomammillary nucleus (TMN), ventral tegmental area (VTA), laterodorsal
tegmental nucleus (LDT), arcuate nucleus (ARN), paraventricular thalamic nucleus
(PVN), peduculopontine nucleus (PPT), amygdala, hippocampus, and cerebellum
(Peyron et al., 1998; Trivedi et al., 1998; Hagan et al., 1999; Nambu et al., 1999; Lu
et al., 2000; reviewed in Sakurai, 2007; Zhang et al., 2011; Tsujino and Sakurai,
2013). The expression of OX1 and  OX2 receptors partly overlaps, but there are also
differences in the expression patterns (Trivedi et  al., 1998; Lu et  al., 2000), which
might reflect partially different functions of the receptor subtypes.
Orexin neurons are innervated by neurons from various parts of the brain. For
example, neurons of the ARN (Broberger et al., 1998), amygdala, basal forebrain,
preoptic area (PO) (Sakurai et al., 2005), DR, lateral parabrachial nucleus,
periaqueductal gray (PAG), lateral and posterior hypothalamus (LH and PH), and
dorsomedial nucleus (Yoshida et al., 2006) send projections to orexin neurons. In
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addition, orexin neurons are regulated by homeostatic signals. They are inhibited by
glucose (Burdakov et al., 2006; Williams et al.,  2008) and activated by some amino
acids (Karnani et al., 2011).
The brain regions connected to orexin neurons either up- or downstream
reflect the physiological functions of the orexinergic system. Next, some of the
functions of orexins are introduced, starting from the best-known and most obvious
effect, the regulation of wakefulness.
Figure 4. Orexin neuron projections and orexin receptor expression in the human
brain. The arrows represent orexin neuron projections from the hypothalamus to other
regions of the brain. LHA/PH, Lateral hypothalamic area/posterior hypothalamus; LC,
locus coeruleus; TMN, tuberomammillary nucleus; LDT, laterodorsal tegmental
nucleus; VTA, ventral tegmental area; PPT, peduculopontine nucleus. From (Sakurai,
2007) with permission of Nature Publishing Group.
2.4.2 Regulation of sleep/wakefulness
Soon after the discovery of orexins and orexin receptors, their involvement in
sleep/wakefulness became apparent, as it was found that the lack of orexins or their
receptors causes narcolepsy. This was first described in dogs and mice (Chemelli et
al., 1999; Lin et al., 1999), and then in human narcoleptic patients. Human
narcoleptic patients have been reported to have dramatically diminished numbers (80–
85% fewer than in healthy subjects) of orexin neurons (Peyron et al., 2000;
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Thannickal et al., 2000), but even more importantly, reduced levels of orexin-A in
their cerebrospinal fluid (CSF) (Nishino et al., 2001). Reduced CSF levels of orexin-
A are now used as one diagnostic criterion for narcolepsy (Mignot et al., 2002).
Narcolepsy with cataplexy is a condition where a patient suffers from daytime
sleepiness and sleep attacks during inappropriate times, and exhibits fragmented sleep
during the night. Cataplexy denotes paralysis of the skeletal muscles for a short period
of time, often, but not always, caused by strong emotions (Adie, 1926; reviewed in
Sakurai, 2013).
Orexin neurons are connected to various brain regions involved in the
regulation of sleep and wakefulness (reviewed in Alexandre et al., 2013). Orexins
activate the neurons in areas such as the DR, TMN and basal forebrain, all of which
are known to be important for the maintenance of wakefulness (Eggermann et al.,
2001). On the other hand, orexin neurons are inhibited during sleep by neurons
projecting from the ventrolateral preoptic area (VLPO) and DR, (Yoshida et al., 2006;
reviewed in Tsujino and Sakurai, 2013). Therefore it is not surprising that orexin
neurons are important for maintaining wakefulness: this has indeed been considered
their main function. On the other hand, they are involved in sustaining a normal sleep
pattern.
There are numerous animal models with no orexin signaling. These models
range from single orexin receptor-knockout mice to PPO-ataxin-3 knockin rats and
mice, where the orexin neurons are postnatally destroyed (reviewed in De la Herran-
Arita and Drucker-Colin, 2012; Kukkonen, 2013b). OX2/OX1-double-knockout and
PPO-deficient mice show similar severe narcoleptic symptoms, whereas OX2
knockout mice are clearly narcoleptic, but with less severe symptoms (Willie et al.,
2001). In dogs, however, malfunctioning of OX2 is enough to produce dramatic
narcoleptic symptoms (Lin et al., 1999; Hungs et al., 2001). Thus, there appear to be
species-specific differences. OX1 knockout mice display only mild fragmentation of
sleep (Willie et al., 2001). The current view, however, is that while the OX2 receptor
is more important for maintaining wakefulness, the OX1 receptor is also needed
(Tsujino and Sakurai, 2013).
Orexins have a balancing effect on the regulation of sleep/wakefulness.
Through negative and positive feedback loops, between orexin neurons and sleep-
promoting and wakefulness-promoting regions of the brain, orexins regulate the
transitions between these two states. When orexin action is absent, the transitions
become more random, causing symptoms of narcolepsy (reviewed in Sakurai, 2007;
Tsujino and Sakurai, 2013).
Besides narcolepsy, other less severe sleep-related problems have been
associated with the orexin system. For example, obstructive sleep apnea has been
suggested to cause damage to neurons mediating wakefulness, including orexin
neurons, and narcoleptic patients quite often suffer from obstructive sleep apnea
(Wang et al., 2013b). There have been studies indicating decreases in PPO, OX2
mRNA, and orexin neurons with age in rodents (Terao et al., 2002; Porkka-Heiskanen
et al., 2004; Kessler et  al., 2011). These changes might contribute to the changes in
sleep with aging, such as the typical decrease in the duration of sleep bouts and
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daytime sleepiness (Porkka-Heiskanen et al., 2004). These findings underline the
importance of the orexin system in controlling wakefulness.
Due  to  its  central  role  in  the  regulation  of  wakefulness,  the  orexin  system is
also a target for drug discovery to develop medications for sleep disorders.
Antagonists of orexin receptors could be useful in treating insomnia, and dual orexin
receptor antagonists (DORAs), such as suvorexant, have especially been under
investigation. According to one study, blocking OX2 alone could promote a more
favorable sleep architecture, since it increases the amount of non-rapid eye movement
(non-REM) sleep, whereas DORAs increase the amount of REM sleep (Betschart et
al., 2013).
2.4.3 Feeding and metabolism
Orexins were named based on their capacity to trigger a feeding response when
centrally administered to rats (Sakurai et al., 1998; Sakurai, 1999); the Greek word
orexis means appetite. Orexin neurons localize in the lateral hypothalamus, which is a
center for appetite regulation. In addition, they send projections to other brain regions
regulating appetite, overall metabolism, and thermoregulation. These regions include
the  LH,  posterior  hypothalamus  (PH),  ARN,  TMN,  and  PVN  (Peyron et al., 1998;
Trivedi et al., 1998). Orexins have been shown to activate AMPK, a key sensor of the
energy status, in the NPY neurons of ARN (Wu et al., 2013). These neurons produce
neuropeptide Y (NPY), a peptide known for its orexigenic effect (Stanley and
Leibowitz, 1984). An interaction between orexin neurons and NPY neurons has also
been suggested in other studies, and there is evidence that the orexin-induced feeding
response is mediated by NPY signaling (Dube et al., 2000; Ida et  al., 2000a; Jain et
al., 2000; Yamanaka et al., 2000; Wu et al., 2013).
In addition to appetite regulation, i.c.v. administration of orexin-A to mice or
anesthetized rats increases whole body energy consumption, as indicated by an
increase in O2 consumption (Lubkin and Stricker-Krongrad, 1998; Wang et al., 2001,
2003). Central administration of orexin-A also indirectly increases energy
consumption through the induction of spontaneous physical activity (SPA) (Jones et
al., 2001; Kotz et al., 2002; Kiwaki et al., 2004). Upon fasting, the expression of PPO
and OX1 mRNA increases (Cai et al., 1999; Lu et al., 2000), and the effect of fasting
on PPO mRNA expression is reversed by injection of the satiety hormone leptin
(Lopez et  al., 2000). The ability of orexin neurons to sense and respond to dietary
amino acids and glucose also suggests that they play a central role in overall energy
balance regulation (Williams et al., 2008; Karnani et al., 2011).
Different  kinds  of  animal  models  have  been  employed  to  explore  the  role  of
orexins in the regulation of feeding and metabolism. PPO-overexpressing mice are
resistant to diet-induced obesity (Funato et  al., 2009), and mice lacking orexin
neurons show hypophagia, but are still obese (Hara et al., 2001). In orexin-ataxin-3
mice and PPO-knockout mice, the genetic background and gender of the mice also
influenced their tendency to gain weight. Female mutant animals gained more weight
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compared to wild-type (wt) females (Fujiki et al., 2006). Even though PPO-knockout
mice have been reported to be hypophagic and gain more weight than wt mice, the
effects of orexin neuron ablation have been reported to be more severe. This is not
surprising, since the orexin neurons express other peptides besides orexins, and the
ablation of orexin neurons also leads to ablation of these other expressed peptides
(Hara et al., 2005). In addition, the neurons in this model are destroyed in adult mice,
thus reducing the ability for compensatory mechanisms to take place. It appears that
even though orexin induces a feeding response, its effect on overall metabolism
counteracts this and results in resistance to weight gain. It is probable that orexins are
more important in regulating overall metabolism than in regulating the feeding
response.
2.4.4 Thermoregulation
One function of orexins closely linked to their ability to regulate overall metabolism
and energy consumption is thermoregulation (Yoshimichi et al., 2001). Orexins
increase the body temperature, but the mechanism of this has been debated. One
regulator of body temperature in mammals is brown adipose tissue (BAT).
Characteristic features of BAT are multilocular lipid droplets, a high content of
mitochondria, and especially the expression of uncoupling protein 1 (UCP1)
(reviewed in Bartelt and Heeren, 2014). UCP1, also known as thermogenin, functions
by uncoupling the mitochondrial electron transport, required for ATP production, and
releasing the energy as heat. This is called non-shivering thermogenesis, and it can be
induced in response to cold or excess caloric intake (so-called diet-induced
thermogenesis). By this mechanism, BAT can affect the overall metabolism, and
protect against obesity induced by high caloric intake (reviewed in Cannon and
Nedergaard, 2010).
In  one  of  the  first  studies  on  the  ability  of  orexins  to  induce  hyperthermia,
orexins were shown to up-regulate the expression of UCP3 mRNA in muscle tissue,
whereas no changes were detected in the expression of UCP1 mRNA in BAT or
UCP2  mRNA  in  white  adipose  tissue  (WAT).  According  to  this  study,  the
thermoregulatory action of orexins was independent of peripheral thermogenesis by
BAT (Yoshimichi et al., 2001). Another study, however, showed that orexins induce
hyperthermia by activating sympathetic nerve firing to interscapular BAT (Monda et
al., 2001). The importance of BAT in orexin-induced hyperthermia has gained more
support from later studies (Monda et al., 2004; Berthoud et al., 2005; Yasuda et al.,
2005; Tupone et al., 2011; reviewed in Madden et al., 2012). Orexins not only
increase BAT thermogenesis, but they are also essential for the development of BAT
(Sellayah et al.,  2011).  All  of  these  studies  have  been  conducted  in  rats.  BAT  is
known to be important for thermoregulation in rodents, but its role in humans has
been debated. Recently, however, studies have concentrated on BAT in humans, and
the possible therapeutic properties of inducing BAT development in adults. The
amount of BAT is inversely proportional with overall adiposity and body mass index
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in humans (reviewed in Kajimura and Saito, 2014). The capacity of orexins to resist
weight gain and adiposity (Funato et  al., 2009) could at least partly be due to their
role in regulating the development and function of BAT.
2.4.5 Reward and addiction
The VTA, nucleus accumbens (NAc) and amygdala are parts of the CNS tightly
involved in reward and addiction. Orexin neurons have projections to all these
structures, and also receive inputs from them (Peyron et al., 1998; Sakurai et al.,
2005; Yoshida et al., 2006). Numerous studies have focused on orexins in drug
addiction and reward. This has been investigated with a number of different drugs and
substances of abuse, including opioids such as morphine (Georgescu et  al., 2003;
Harris et al., 2005; Narita et  al., 2006; Sharf et  al., 2008) and heroin (Smith and
Aston-Jones, 2012), central stimulants such as cocaine (Boutrel et al., 2005; Borgland
et al., 2006; Espana et al., 2010; Espana et al., 2011; Hollander et al., 2012; Yeoh et
al., 2012) and amphetamine (Quarta et  al., 2010; Hutcheson et al., 2011), cannabis
(Rotter et al., 2012), ethanol (Lawrence et al., 2006; Shoblock et al., 2011; Brown et
al., 2013)}, and nicotine (Pasumarthi et al., 2006; Hollander et al., 2008; Plaza-
Zabala et al., 2010; Plaza-Zabala et al., 2013). Food can also function as a rewarding
stimulus and activate the same pathways as addictive drugs (Harris et al., 2005;
Kelley et al., 2005; Choi et  al., 2012; Kay et al.,  2014).  Therefore,  it  is  difficult  to
distinguish between the actions orexins in appetite regulation and reward.
The results of studies on addiction and relapse have been variable, and have
depended on the drugs employed and the experimental designs. Orexins were first
shown to have a role in morphine dependence and subsequently also in the
reinstatement of cocaine-seeking (Georgescu et  al., 2003; Boutrel et al., 2005).
However, in one of the first papers on the role of orexins in reward-seeking, besides
morphine and cocaine, food was also used as a rewarding stimulus for rats (Harris et
al., 2005). Conditioned place preference (CPP) is a widely used method in addiction
research. In CPP experiments animals are taught to associate one area (compartment
of a cage) with a stimulus, such as a certain drug, while another area is associated
with  the  absence  of  the  stimulus  (only  the  vehicle  of  the  drug).  When  the  training
session for associating the areas with different stimuli is over, the animal is allowed to
freely move between these areas. If the animal spends more time in the area
associated with the drug as compared to the control area, this is called CPP (Prus et
al., 2009). All of the investigated rewarding stimuli (morphine, cocaine and food) led
to similar outcomes in this study. There was a positive correlation between CPP and
c-Fos  activation  in  orexin  neurons.  Injection  of  an  OX1 antagonist, SB-334867,
decreased CPP. On the other hand, an extinguished CPP was reinstated by activating
orexin neurons. These results indicate that orexins are involved in reward seeking,
drug addiction and relapse (Harris et al., 2005). PPO-knockout mice were reported
not to develop morphine-induced CPP, which supports the idea that orexins are
involved in reward seeking and addiction (Narita et al., 2006). In another study,
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however, PPO-knockout mice did not show altered CPP or locomotor responses to
morphine (Sharf et al., 2010). Despite the discrepancy between these studies, most of
the evidence supports the involvement of orexins in reward and addiction. Some
investigators have even suggested the orexin system as a target for pharmaceutical
drugs for treating addiction (Boutrel et al., 2013; Xu et al., 2013).
2.4.6 Synaptic plasticity, learning, and memory
Addiction involves complex neural adaptations, and thus requires synaptic plasticity
in parts of the brain involved in reward processing and addiction (reviewed in Kauer
and Malenka, 2007). Addiction can therefore be thought of as one (pathological) form
of learning and memory. As discussed above, orexins are involved in many aspects of
addiction, but they have also been shown to be involved in other types of learning
(van den Pol et al., 2002; Selbach et al., 2004; Akbari et al., 2011; Yang et  al.,
2013a).
For learning to occur, synapses have to be able to weaken or strengthen
according to their activity. This is called synaptic plasticity, and the forms of these
activity-dependent changes in synaptic strength are called long-term potentiation
(LTP) and long-term depression (LTD) (Bliss and Lomo, 1973; Alger and Teyler,
1976; Dunwiddie and Lynch, 1978; reviewed in Kauer and Malenka, 2007). LTP and
LTD  were  first  reported  to  occur  in  the  hippocampus,  but  were  soon  shown  to  also
take place elsewhere in the brain (Kirkwood et al., 1993). There are different
mechanisms  of  LTP  and  LTD,  but  probably  the  most  studied  and  understood  is N-
methyl-D-aspartate receptor (NMDAR, a subfamily of ionotropic glutamate
receptors)-dependent LTP. This type of LTP requires that the postsynaptic membrane
is strongly depolarized at the same time as the NMDARs are activated by glutamate.
This leads to an increase in the intracellular Ca2+ concentration in the postsynaptic
neuron, and through activation of various signaling cascades, this ultimately leads to
an increase in the number of α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid
receptors (AMPARs, another family of ionotropic glutamate receptors) in the
postsynaptic cell membrane, while the number of NMDARs remains unaltered. These
changes are followed by structural changes in the synapse, such as enlargement of
dendritic spines and increased postsynaptic densities (reviewed in Kauer and
Malenka, 2007).
Orexin-A has been shown to enhance synaptic strength in VTA dopamine
neurons (Borgland et al., 2006). First, orexin-A induced a rapid enhancement of
synaptic strength, probably by translocation of NMDARs to the postsynaptic
membrane from an intracellular compartment. This was followed 3–4 hours later by
increased numbers of AMPARs on the postsynaptic membrane. The OX1 antagonist
SB334867 blocked these responses (Borgland et al., 2006). In CA-1 hippocampal
neurons, orexin-A has been reported to induce LTD (Doreulee et al., 2009), and in
cortical neuron cultures, incubation with either orexin-A or -B reduced the expression
of  NMDAR  and  AMPAR  subunit  mRNA  (Yamada et al., 2008). These results
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indicate that orexins could produce both LTP and LTD, and therefore mediate
learning effects.
Many behavioral studies support the idea that orexins are important for
learning and memory. I.c.v. injection of orexin-A improved active and passive
avoidance learning in mice and rats (Jaeger et al., 2002; Telegdy and Adamik, 2002).
The OX1 antagonist SB334867 has been shown to impair performance in memory
tests, such as the Morris water maze, and especially to influence memory acquisition
and consolidation (Akbari et al., 2006, 2007; Akbari et al., 2008). SB334867 has also
been shown to impair motor learning in the cerebellum (Chen et al., 2013) and threat
learning in the LC (Sears et al., 2013).
The involvement of orexins in learning has also been investigated using OX1
receptor-knockout mice and orexin-ataxin-3 mice. OX1-knockouts showed deficits in
the formation of emotional memory, as assessed by their performance in fear-
conditioning tests (Soya et al., 2013). Orexin-ataxin-3 mice had impaired long-term
social memory, which was partially restored by administration of exogenous orexin-A
(Yang et al., 2013a). A decreased number of orexin neurons and reduced CSF orexin-
A levels have been reported in humans suffering from Alzheimer's disease (Fronczek
et al., 2012). This disease is characterized by cognitive decline, but it is also
accompanied by daytime sleepiness and other sleep problems resembling symptoms
of narcolepsy.
2.4.7 Pain modulation
Reward circuits of the CNS overlap with nociceptive circuits (Borsook et  al., 2007).
Brain  regions  such  as  the  amygdala,  NAc,  VTA,  periaqueductal  grey  (PAG)  and
lateral prefrontal cortex have been shown to be involved in both reward and pain
processing circuits. Furthermore, chronic pain has been shown to alter the reward
circuitry (Borsook et al., 2007). Considering the role of orexins in reward and drug
addiction, it is not surprising that orexins are also involved in pain processing.
Orexin neurons send projections to brain regions involved in pain processing,
but  also  to  the  spinal  cord,  which  is  important  for  pain  transmission  (van  den  Pol,
1999; Bingham et al., 2001). In the first studies on the role of orexins in pain
modulation, it was shown that intravenous (i.v.) injection of orexin-A caused
analgesia in hyperalgesic rats and mice (Bingham et al., 2001). This effect was
blocked by an orexin receptor antagonist, but not by the opioid receptor antagonist
naloxone. This suggests that the orexin system modulates nociception independently
of the opioid system (Bingham et al., 2001). In another study intrathecal injection of
orexin-A produced an analgesic effect, which was abolished by pre-treatment with
SB-334867. This implies that the analgesic effects of orexin-A in the spinal cord are
mediated by OX1 receptors. Orexin-B did not have similar effects (Yamamoto et al.,
2002). In rat models of neuropathic pain, orexin-A showed analgesic effects and
reduced allodynia symptoms. These effects apply to situations of post-operative pain
(Cheng et al., 2003) and sciatic nerve injury-induced pain (Yamamoto et  al., 2003;
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Suyama et al., 2004), as well as diabetic neuropathic pain models (Kajiyama et al.,
2005).
Some studies have implied that primary headaches such as cluster headache
and migraine could be connected with the orexin system (Bartsch et al., 2004;
Holland et al., 2005; Sarchielli et al., 2008). Certain variants of the OX1 gene increase
the susceptibility to migraine (Rainero et  al.,  2011).  One  of  the  factors  causing
migraine headaches is trigeminal nerve activation and subsequent dilation of cranial
blood vessels. Orexin-A inhibits this vasodilatation, and might in this way relieve the
migraine pain (Holland et al., 2005).
Orexin-A modulates different kinds of pain on the spinal cord level, but also in
various brain regions, which include the periaqueductal grey (PAG) (Azhdari
Zarmehri et al., 2011; Ho et  al., 2011), the oral part of the pontine reticular nucleus
(PnO) (Watson et  al., 2010), the lateral paragigantocellular nucleus (Erami et al.,
2012), VTA, and NAc (Azhdari-Zarmehri et al., 2013a; Sadeghi et al., 2013). In the
PAG, paragigantocellularis lateralis, and PnO, orexin-A injections had analgesic
effects in hot plate and formalin tests (Azhdari-Zarmehri et al., 2013b). In the VTA
and NAc, the OX1 receptor antagonist SB334867 inhibited analgesic effects induced
by carbachol, suggesting that orexin receptors lie downstream of cholinergic neurons
producing analgesia. There is also evidence that OX1 receptors might have a role in
morphine-induced analgesia, because SB334867 has also decreased morphine-
induced antinociception (Azhdari-Zarmehri et al., 2013b).
2.4.8 Functions in the gastrointestinal tract
The expression of PPO, OX1, and OX2 mRNA in the small intestine and pancreas of
rats was verified relatively soon after the discovery of orexins in the hypothalamus
(Kirchgessner and Liu, 1999). OX1, OX2, orexin-A and orexin-B were also
histochemically detected in different parts of the gastrointestinal tract of the rat,
mouse and guinea pig. Orexins increase the mobility of isolated guinea pig ileum
segments, and the small intestine of the mouse in situ (Kirchgessner and Liu, 1999;
Satoh et  al., 2001). Orexins were also shown to increase gastric acid secretion when
administered centrally (Takahashi et al., 1999).
Further studies have confirmed that orexins increase both gastric acid and also
duodenal bicarbonate secretion in rats (Flemström et al., 2003; Yamada et al., 2005;
Bengtsson et al., 2007). These effects of orexin-A were abolished by pretreatment
with SB334867, suggesting that they were mediated by OX1 receptors (Yamada et al.,
2005; Bengtsson et al., 2007). The effects of orexins on duodenal secretion are
dependent on the feeding status of the animals; orexins increase the duodenal
bicarbonate secretion in fed rats, but not in overnight-fasted rats (Flemström et  al.,
2003; Bengtsson et al., 2007).
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2.4.9 Regulation of endocrine secretion
Orexin receptors are expressed in many organs that have endocrine functions. The
functions of orexins in these tissues have been extensively investigated, but the direct
actions, in particular, are still somewhat unclear. In addition, physiological
concentrations of orexins in peripheral tissues are difficult to measure, and the source
of orexins in these tissues is not yet resolved (reviewed in Kukkonen, 2013b). There
is, however, a considerable amount of evidence that orexins are involved in the
regulation of secretion of certain hormones.
The expression of both orexins and their receptors has been reported in the
pituitary glands of many species, including rats and humans (Date et al., 2000; Blanco
et al., 2001). The expression levels of orexin receptors in the pituitary vary according
to hormonal changes, for example during the oestrus cycle in pigs (Kaminski et al.,
2010) and following gonadectomy in rats (Jöhren et al., 2003). I.c.v. injection of
orexin-A has been shown to lead to an increase in plasma adrenocorticotropic
hormone (ACTH) and corticosterone levels in rats (Al-Barazanji et al., 2001). In the
same study, corticotropin-releasing factor (CRF) and arginine vasopressin (AVP)
mRNA expression was also reported to increase in the hypothalamic parvocellular
paraventricular nucleus following orexin-A injection (Al-Barazanji et al., 2001).
These results were supported by other studies, one of which also implicated that the
regulation of CRF release by orexins is mediated by NPY (Russell et al., 2001),
whereas another study demonstrated orexin-mediated stimulation of CRF and ACTH
secretion in the absence of NPY activity (Moreno et al., 2005).
In cultured cells, the effects of orexins are somewhat contradictory. In ovine
somatotropes, orexins increased growth hormone release, induced by growth
hormone-releasing hormone (Chen and Xu, 2003), whereas in porcine cultured
anterior pituitary cells, orexin-B inhibited growth hormone but increased luteinizing
hormone release (Barb and Matteri, 2005). Orexin-induced luteinizing hormone
secretion was also detected in cultured pituitary cells of immature but not mature
female rats (Martynska et  al., 2011). Furthermore, orexins were shown to reduce the
oxytocin and vasopressin release induced by epinephrine, histamine, or serotonin in
rat neurohypophyseal cell cultures (Kis et al., 2011; Ocsko et al., 2012).
In narcoleptic humans, ACTH and corticol secretion was reported to be less
regular than in healthy subjects (Kok et al., 2002). The timing of growth hormone
release in narcoleptic humans has also been shown to differ from healthy subjects.
Narcoleptic patients secreted approximately 50% of their daily growth hormone
during the day, whereas healthy subjects secrete only about 25%, and most of the
secretion occurs during the night (Overeem et al., 2003). However, in these reports,
other possible factors affecting the hormone secretion cannot be ruled out. Therefore
the involvement of orexins in these phenomena is difficult to evaluate. It can be
speculated that orexins affect hormone release from the pituitary gland, but the results
of the studies so far conducted have been inconsistent, perhaps due to differences in
the species and cell types investigated, or the methods employed.
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As described above, orexins might regulate hormone secretion from the
pituitary gland, including ACTH secretion. The target of ACTH is the adrenal cortex,
and orexins affect the function and secretion of the adrenal cortex via this pathway,
but there is also evidence of direct effects on the adrenal gland. The expression of
either one or both orexin receptors has been reported in the adrenal glands of many
species, including rats (Lopez et al., 1999; Malendowicz et al., 1999), humans
(Karteris et al., 2001; Mazzocchi et al., 2001; Randeva et al., 2001), pigs (Nanmoku
et al., 2002), and cows (Kawada et al., 2003). In cultured rat adrenocortical cells,
orexins stimulated corticosterone secretion (Malendowicz et al., 1999), and chronic
exposure to systemically administered orexins increased aldosterone and
corticosterone secretion in female rats (Malendowicz et al., 2001). In another study,
i.c.v. injections of both orexin-A and -B induced corticosterone production in male
rats, whereas intraperitoneal injections did not (Jaszberenyi et al., 2000). In human
adrenocortical cells, orexin-A induced corticosterone and cortisol secretion, but the
receptor mediating this was suggested to be OX2 in one study (Randeva et  al., 2001)
and OX1 in another (Ziolkowska et al., 2005).
Orexins up-regulate the expression of the steroidogenic acute regulatory
protein in human adrenal H295R cells (Ramanjaneya et al., 2008). In the same cell
line, mRNA for steroidogenic enzymes, such as CYP11B1 and CYP11B2, was also
increased following treatment with orexin-A and -B, although orexin-B was less
potent (Wenzel et al., 2009). Thus, according to studies performed with primary cells
and cell lines, it appears that orexins can directly modulate the endocrine activity of
adrenal cells.
Both PPO and OX1 mRNA have been reported to increase during fasting (Cai
et al., 1999; Lu et al., 2000), which is a hypoglycemic situation, and glucose has been
shown to inhibit orexin neurons (Williams et al., 2008). Therefore, it would make
sense that orexins would be involved in the regulation of blood glucose levels by
regulating the secretion of insulin or glucagon from the pancreas. There have been
studies demonstrating that central orexins regulate pancreatic exocrine secretion via
activation of the vagal efferent nerve (Miyasaka et al., 2002; Wu et al., 2004), and it
could therefore be possible that they also affect endocrine secretion. The expression
of orexins and their receptors has also been shown in the pancreas of rats and humans
(Kirchgessner, 2002; Nakabayashi et al., 2003; Ehrstrom et al., 2005; Adeghate et al.,
2010; Adeghate and Hameed, 2011). The effects of orexins on the endocrine secretion
of the pancreas are far from clear. There has been one study showing that orexins
increase glucagon, and decrease glucose-induced insulin secretion in isolated
pancreatic islets and in fasted rats (Ouedraogo et  al., 2003), while two other groups
have reported inhibition of glucagon secretion in perfused rat pancreas, isolated rat
pancreatic islets, and an endocrine pancreatic cancer cell line (InR1-G9) (Göncz et al.,
2008), and stimulation of insulin secretion from rat pancreatic islets (Nowak et al.,
2005).
OX1 mRNA  expression  has  been  reported  in  the  ovaries  and  testes  of  rats
(Jöhren et al.,  2001),  and  in  the  testes  of  sheep  (Zhang et al., 2005). Both orexin
receptors are expressed in the human testis, penis, epididymis and seminal vesicle
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(Karteris et al., 2004). Orexin-A induced testosterone secretion from rat testis both in
vitro and in vivo (Barreiro et al., 2004), and orexin-A-induced testosterone secretion
was also reported in the testis of the South American camelid, alpaca (Liguori et al.,
2012).
2.4.10 Functions in white adipose tissue
Both OX1 and OX2 are expressed in human white adipose tissue (WAT) (Digby et al.,
2006). When isolated adipocytes from human omental and subcutaneous (s.c.)
adipose tissue were treated with orexins, the expression of peroxisome proliferator-
activated receptor γ (PPARγ) was increased, whereas hormone-sensitive lipase
activity as well as glycerol release were decreased (Digby et al., 2006).
In the 3T3-L1 preadipocyte cell line, orexin-A increased proliferation
(Zwirska-Korczala et al., 2007) but not differentiation to mature adipocytes
(Skrzypski et al., 2012). Orexin-A also increased glucose uptake by translocating the
glucose transporter GLUT4 to the plasma membrane, and increased the accumulation
of triglycerides in differentiated 3T3-L1 adipocytes, and primary adipocytes isolated
from rats (Skrzypski et al., 2011). GLUT4 expression was increased in differentiated
3T3 L1 adipocytes, whereas in 3T3-L1 preadipocytes, the expression of PPARγ was
increased following treatment with orexin-A (Shen et al., 2013). In the same study,
OX1 receptor levels were decreased in the omental adipose tissue of obese rats, and
there was a negative correlation between OX1 expression levels and body fat mass,
plasma cholesterol, and triacylglycerol levels, and the fasting insulin level (Shen et
al., 2013).
It is interesting that while the direct effects of orexins in adipocytes inhibit
lipolysis and increase lipogenesis (Digby et al., 2006; Skrzypski et al., 2011), i.c.v.
injection of orexin-A has been shown to stimulate lipolysis in WAT via autonomic
nerve activity (Shen et al., 2008). This effect was, however, dependent on the dose; a
small dose of orexin-A decreased lipolysis, while a higher dose increased it (Shen et
al., 2008).
The regulation of WAT by orexins is more complicated than simply their
direct effects on adipocytes. Even though it appears that orexins increase the amount
of WAT by increasing their proliferation and lipogenesis, the net effect of orexins is a
decrease in adiposity and resistance to weight gain, as judged by the phenotypes of,
for example, PPO-overexpressing mice, or orexin neuron-ablated mice (Hara et al.,
2001; Funato et al., 2009).
34
2.5 Endocannabinoids
Endocannabinoids, such as 2-AG and anandamide, are lipid mediators that function in
the CNS, but also in the periphery. Their synthesis and degradation are discussed in
section 2.3.4. This section concentrates on their receptors and physiological functions.
2.5.1 Receptors and their signaling
The plant Cannabis sativa has been used for medication and recreational purposes for
hundreds of years, but the main psychoactive compound, Δ9-tetrahydrocannabinol
(Δ9-THC), was identified and its chemical structure revealed in the 1960s (reviewed
in Fonseca et al., 2013). After this discovery, it took almost 30 years to resolve the
mechanism by which Δ9-THC exerts its effects in animals.
In 1984, Howlett et al. (1984) reported that Δ8-THC  and  Δ9-THC mediated
inhibition of AC activity in neuroblastoma cells. At the time, receptors for
cannabinoids had not yet been found, but the effect of cannabinoids on AC was
sensitive to pertussis toxin, indicating the involvement of Gi proteins (Howlett et al.,
1986). The search for cannabinoid receptors continued, and the 3H-labeled analgesic
cannabinoid CP55,940 was used to determine the pharmacology and binding kinetics
of the putative cannabinoid receptors (Devane et al., 1988), as well as the localization
of cannabinoid binding sites in the brain (Herkenham et al., 1990). In 1990, the
cloning and expression of a cDNA that encoded a GPCR, which fulfilled the criteria
for being a cannabinoid receptor, was reported (Matsuda et al., 1990). Later, another
receptor for cannabinoids was cloned from macrophages in the spleen (Munro et  al.,
1993). These cannabinoid receptors are rhodopsin-like GPCRs called CB1 and  CB2,
respectively. CB1 is mainly expressed in the CNS, while CB2 is the peripheral
receptor and mainly found in cells of the immune system (reviewed in Kano et  al.,
2009). Despite this rough division into central and peripheral cannabinoid receptors,
CB1 is not restricted to the CNS, but is also expressed in many peripheral locations
(reviewed in Pagotto et al., 2006). The endogenous ligand anandamide was found
around the same time as CB1 (Devane et al., 1992), followed by the discovery of 2-
AG, another endogenous ligand, a few years later (Sugiura et al., 1995). These and
other endogenous cannabinoid receptor agonists are called endocannabinoids.
Coupling to Gi proteins was implied for cannabinoid receptors even before the
receptors had been identified (Howlett et al., 1986). Both CB1 and  CB2 receptors
couple to Gi, and have been shown to inhibit AC (Howlett, 1984; Kaminski et al.,
1992). Coupling to other G-proteins, such as Gs and Gq,  has also been suggested for
CB1 (Glass and Felder, 1997; Lauckner et al., 2005; Chen et al., 2010). Cannabinoid
receptors utilize various pathways in their signaling, in addition to inhibiting AC. CB1
and CB2 activate ERK1 and ERK2, PKC and PI3K (Bouaboula et al., 1995;
Bouaboula et al., 1996; Sanchez et al., 2003). CB1 activates inwardly rectifying and
A-type K+ channels (Henry and Chavkin, 1995; Mackie et al., 1995; Mu et al., 1999)
and  inhibits  N-  and  P/Q-type  Ca2+ channels  and  M-  and  D-type  K+ currents (Pan et
al., 1996; Twitchell et al., 1997; Mu et al., 1999; Schweitzer, 2000). It has been
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suggested that cannabinoid receptors show constitutive activity, i.e. signaling activity
in the absence of an agonist (Bouaboula et al., 1997; reviewed in Console-Bram et al.,
2012). This view has, however, been challenged (Savinainen et al., 2003).
CB1 receptors  are  one  of  the  most  abundant  GPCRs  in  the  CNS.  They  are
expressed throughout the brain, especially in the presynaptic locations (reviewed in
Kano et al., 2009). Endocannabinoids are involved in so-called retrograde synaptic
transmission, where activation of the postsynaptic neuron leads to the release of
endocannabinoids into the synaptic cleft. This released endocannabinoid then binds to
CB1 receptors in the presynaptic neuron and inhibits further neurotransmitter release.
The released endocannabinoids often also affect other nearby synapses in a paracrine
manner. The end result, inhibition or activation of action potentials, depends on the
nature of the synapse: CB1 receptors have been shown to regulate the release of
several neurotransmitters, such as glutamate, GABA, acetylcholine, norepinephrine,
dopamine, and serotonin (reviewed in Kano et al., 2009).
CB1 and  CB2 are not the only targets for endocannabinoids. Anandamide is
known to activate TRPV1, and both anandamide and 2-AG can activate PPARs and
GPR55 (reviewed in Kano et al., 2009; Fonseca et al., 2013).
2.5.2 Physiology of endocannabinoids
Endocannabinoids are involved in numerous physiological functions. This is due to
the  wide  expression  of  CB1 in the brain, especially in the cerebral cortex,
hippocampus, and amygdala, and because they act as retrograde transmitters in a wide
array of synapses (reviewed in Kano et al., 2009). In addition to functions in the CNS,
endocannabinoid signaling is also found in the periphery of the body, where it is
involved in the regulation of overall metabolism, endocrine organs, and the immune
system (reviewed in Pagotto et al., 2006). The functions regulated by
endocannabinoids are diverse and have been extensively studied, but only the most
central functions will be briefly described here. There are many excellent reviews on
the different aspects of endocannabinoid physiology.
Synaptic plasticity, learning, and memory
The hippocampus is a part of the brain involved in learning and memory, and both
LTP and LTD were first reported to occur in hippocampal neurons (Bliss and Lomo,
1973; Alger and Teyler, 1976; Dunwiddie and Lynch, 1978). As mentioned above,
hippocampal neurons express high levels of CB1, and through their action in
retrograde synaptic transmission, endocannabinoids are involved in learning. They
can produce short-term inhibition of the synapse, but also of LTD and LTP (Ohno-
Shosaku et  al., 2001; Wilson and Nicoll, 2001; Carlson et al., 2002; Chevaleyre and
Castillo, 2003).
Studies on CB1-knockout mice suggest that endocannabinoids are involved in
memory processes by facilitating memory extinction and forgetting processes (Varvel
and Lichtman, 2002). CB1-knockout mice have enhanced memory, especially fear
36
memory (Reibaud et al., 1999; Jacob et al., 2012). The enhancement of fear memory
could be explained by the crosstalk between glucocorticoids and endocannabinoids
(reviewed in Akirav, 2013). Endocannabinoids negatively regulate the hypothalamic-
pituitary-adrenal axis, thus inhibiting the release of corticosterone, a typical stress
hormone (Patel et al., 2004). Fearful stimuli induce stress responses in animals, and
endocannabinoid release attenuates this response, therefore also affecting the memory
process. Knocking out the CB1 receptor leads to dysregulation of the hypothalamic-
pituitary-adrenal axis (Cota et  al., 2007). Typical features of post-traumatic stress
disorder are vivid memories and nightmares about a traumatic event. Some studies
suggest that cannabinoids could be used to treat this disorder, because they have been
reported to decrease these symptoms (reviewed in Akirav, 2013). The
endocannabinoid system has been shown to mediate the extinction of aversive
memories (Laricchiuta et al., 2013).
Pain modulation
Cannabinoids have been used to treat pain, and they have also been shown to be
effective in decreasing nausea and vomiting (reviewed in Sharkey et al., 2014). These
features make them useful for treating, for example, cancer patients suffering from
chemotherapy-induced nausea. Cannabinoids suppress spinal and thalamic
nociceptive neuron activity, thereby mediating analgesia (Zogopoulos et al., 2013).
CB1 and CB2 receptors, but also TRPV1 channels, mediate these effects. Interestingly,
anandamide has been shown to produce analgesic effects in the spinal cord of rats
suffering from neuropathic pain, by both CB1 and TRPV1 activation (Starowicz et al.,
2012). TRPV1 is activated by painful stimuli, such as noxious heat and capsaicin, and
anandamide at least partly mediates its analgesic effects by desensitizing TRPV1
(Starowicz et al., 2012).
In human fetal astrocytes, the interleukin-1β (IL-1β)-induced production of
inflammatory mediators was inhibited by WIN55,212-2, a synthetic cannabinoid,
which activates both CB1 and  CB2 receptors, suggesting a mechanism by which
cannabinoid receptors attenuate inflammation in the brain (Sheng et al., 2005). In
addition to inhibiting the production of inflammatory mediators, anandamide induces
the release of IL-6 from mouse astrocytes (Molina-Holgado et al., 1998). IL-6 can
function as a pro-inflammatory cytokine, but it also has anti-inflammatory effects
(reviewed in Petersen and Pedersen, 2005). Endocannabinoids are effective in the
treatment of inflammatory pain, and the inhibition of enzymes metabolizing them,
mainly FAAH, has been studied as one possible strategy for treating chronic
inflammatory pain disorders (Naidu et al., 2010).
The endocannabinoids also mediate their analgesic action by modulating pain
perception in the brain. The brain regions involved in the analgesic effects of
cannabinoids were studied by local injections of WIN55,212-2, and measuring the
effect of thermal noxious stimuli in the tail-flick test (Martin et al., 1995). According
to this study, cannabinoids mediate analgesia via the dorsolateral PAG and DR
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(Martin et al., 1995). Subsequently, regions such as the superior colliculus, amygdala,
the noradrenergic A5 region of the brainstem, and lateral posterior and submedial
nuclei of the thalamus have been added to the list of brain regions mediating
cannabinoid-induced analgesia (Martin et al., 1999). The involvement of the PAG in
cannabinoid-mediated analgesia has been supported by other studies (Lichtman et al.,
1996; Walker et al., 1999; Galdino et al., 2014). Electrical activation of PAG neurons
resulted in the release of anandamide, and subcutaneous injections of formalin, a
painful stimulus, also produced this effect (Walker et al., 1999). Interestingly, aerobic
exercise-induced anti-nociception is also mediated, at least in part, via the
endocannabinoid system in the PAG. CB1 receptor expression and activity in the PAG
was reported to increase in response to aerobic exercise. Plasma endocannabinoid
levels also increased after exercise, implicating both the central and peripheral action
of endocannabinoids in aerobic exercise-induced analgesia (Galdino et al., 2014).
Neuroprotection
Partly because of their anti-inflammatory effects, endocannabinoids are
neuroprotective. Anandamide protects rat cerebral cortical neurons from ischemia
both in vitro and in vivo (Nagayama et al., 1999; Sinor et  al., 2000). In traumatic
brain injury, reactive oxygen species (ROS), massive glutamate release, and
inflammatory agents cause damage to the brain cells (reviewed in Mechoulam et al.,
2002). Endocannabinoids have been shown to inhibit the release of ROS and
inflammatory agents in human astrocytes, but also inhibit the release of tumor
necrosis factor α (TNFα) in murine peritoneal macrophages (Gallily et al., 2000;
Sheng et al., 2005). Endocannabinoids also inhibit glutamate release (Shen et  al.,
1996). One study demonstrated that 2-AG levels are increased after closed head injury
in mice, and that 2-AG inhibited the activation of nuclear factor-κB in mice, thereby
inhibiting the release of pro-inflammatory cytokines (Panikashvili et al., 2005). This
effect was attenuated by the CB1 antagonist SR141716, and 2-AG did not produce
these effects in CB1-knockout mice. These mice also showed impaired recovery after
closed head injury when compared with wt mice (Panikashvili et al., 2005). In
addition to these effects, endocannabinoids have been shown to counteract
endothelin-1, a potent vasoconstrictor, thus restoring blood flow to the damaged brain
tissue, as (reviewed in Mechoulam et al., 2002). Endocannabinoid signaling via CB1
mediates regeneration and neural progenitor cell proliferation after excitotoxic injury
(Aguado et al., 2007). Therefore, endocannabinoids are involved in all aspects of
neuroprotection following brain injuries.
Feeding, reward, and metabolism
Endocannabinoids increase appetite (Di Marzo et al., 2001) and hedonic aspects of
food. CB1 expression increases upon fasting, and injections of anandamide have been
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reported to cause overeating in rats (Williams and Kirkham, 1999; Burdyga et al.,
2004). Endocannabinoids increased the intake of highly palatable food, even in non-
deprived rats (Higgs et al., 2003; Shinohara et al., 2009). The increase in highly
palatable food consumption was prevented by the CB1 inverse agonists/antagonists
AM251 (DiPatrizio and Simansky, 2008) and SR141716 (also known as rimonabant)
(Mathes et al., 2008). There have been studies, however, implicating that SR141716
decreases overall food intake, and not selectively the intake of highly palatable food
(Freedland et  al., 2000; Verty et  al., 2004). Endocannabinoids appear to regulate the
hedonic and rewarding aspects of feeding, rather than just feeding when nutrition is
needed. A recent study reported that an increase in the plasma 2-AG concentration
was associated with hedonic eating in humans (Monteleone et al., 2012).
Endocannabinoids are involved in reward circuits (reviewed in Gardner, 2005), and
they have been shown to directly modulate the activity of dopaminergic neurons in
the VTA (Pillolla et al., 2007). The reward circuits are also essential for addiction.
There is evidence of endocannabinoid involvement in addiction to substances such as
ethanol (Arnone et al., 1997), cocaine (De Vries et al., 2001), morphine (Gonzalez et
al., 2003), and nicotine (De Vries et al., 2005).
Endocannabinoids increase appetite, but they also regulate energy metabolism
both centrally and peripherally (reviewed in Di Marzo and Matias, 2005; O'Keefe et
al., 2014). CB1-knockout mice are lean and resistant to obesity due to their decreased
food intake, but also because of metabolic factors (Cota et al., 2003). Even when fed a
high-fat diet, CB1-knockout mice did not become obese and their plasma insulin and
leptin levels remained low (Ravinet Trillou et  al., 2004). The use of SR141716 has
been associated with a similar phenotype: when mice with diet-induced obesity were
treated with orally administered SR141716, it led to a decrease in their body weight,
especially their adiposity (Jbilo et al., 2005). The morphology and function of the
adipocytes in these mice also changed towards that of lean mice. Energy expenditure
and lipolysis in adipocytes were increased, and glucose homeostasis was improved.
Obesity is often accompanied by inflammation, caused by pro-inflammatory factors
released within the adipose tissue. SR141716 also decreased the release of pro-
inflammatory factors from adipocytes (Jbilo et al., 2005). In addition, an increased
tendency towards conversion to brown adipocytes was reported in cultured adipocytes
derived from CB1-knockout mice (Wagner et al., 2011).
Blocking  the  action  of  CB1 also has possibly beneficial metabolic effects in
muscle  cells.  Injections  of  the  CB1 agonist HU210 induced a reduced uptake of
glucose in skeletal muscles of wt mice, and this effect was prevented with AM251
(Song et al., 2011). In cultured myotubes from lean and obese humans, AM251
increased the expression of genes that are important for fatty acid oxidation (Cavuoto
et al., 2007). Because antagonism of CB1 action has been shown to be beneficial for
weight loss and to counteract the metabolic consequences of obesity, such as insulin
resistance, SR141716 was used as an anti-obesity drug for humans. However, it was
withdrawn from the market because of serious side effects, such as depression.
Therefore, a CB1 blocker that would not cross the blood–brain barrier, but would still
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have the desired effects in the periphery, could be ideal as an anti-obesity drug
(reviewed in O'Keefe et al., 2014).
2.6 Interaction of orexin and cannabinoid systems
The orexin and cannabinoid systems of the brain share many functions. They are both
involved in pain modulation, the regulation of appetite, reward, memory, and the
regulation of overall metabolism. Some studies have suggested interactions between
these two systems.
2.6.1 Evidence from electrophysiological studies
The first electrophysiological evidence for interactions between orexin and
cannabinoid systems came from a patch-clamp study on a slice preparation of the DR
from male rats (Haj-Dahmane and Shen, 2005). In the serotonergic neurons of the
DR, orexin-B induced a depression of glutamate-mediated synaptic currents. This
effect was mimicked by WIN55,212-2 and abolished by AM-251, suggesting the
involvement of CB1 receptors. The inhibition of glutamate release was also
counteracted by inhibition of G-protein signaling in postsynaptic neurons by GDPβS,
a non-hydrolyzable analog of GDP. These results were interpreted to suggest that
orexin-B regulates the activity of DR serotonergic neurons by the postsynaptic release
of endocannabinoids. These endocannabinoids then inhibit glutamate release to
serotonergic neurons presynaptically. Serotonergic neurons are activated during
wakefulness, and an inhibitory action of orexin-B, an arousal-increasing neuropeptide,
on these neurons therefore seems paradoxical. The authors, however, speculated that
this negative feedback induced by endocannabinoid release is necessary for
preventing excessive excitation of the neurons and therefore for stable firing (Haj-
Dahmane and Shen, 2005). According to this study, the interaction of orexins and
endocannabinoids is important in the physiological regulation of arousal.
Another group utilized the patch clamp approach to investigate the actions of
cannabinoid agonists and antagonists on melanin concentrating hormone (MCH)
neurons and orexin neurons in mouse hypothalamic slices (Huang et al., 2007).
WIN55,212-2 caused depolarization and an increase in spike frequency in MCH
neurons, while in orexin neurons it caused hyperpolarization and reduced spontaneous
firing. Both of these effects, the activation of MCH neurons and inhibition of orexin
neurons, were prevented by AM-251. Furthermore, the effects on MCH neurons were
inhibited by bicuculline, a GABAA antagonist, whereas the ionotropic glutamate
antagonists AP-5 and CNQX abolished the effects on orexin neurons. These results
were interpreted to indicate that MCH neurons are innervated by GABAergic neurons
and orexin neurons by glutamatergic neurons, and the release of endocannabinoids
from MCH and orexin neurons and their retrograde synaptic effects therefore result in
the effects described. The activation of MCH neurons might contribute to the
appetite- and weight-increasing effects of cannabinoids, while their inhibitory actions
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on orexin neurons could, according to the authors, explain how cannabinoids decrease
cognitive arousal (Huang et al., 2007).
One common function for the orexin and endocannabinoid systems is the
modulation of pain. The PAG is a brain region that initiates inhibition of nociception
(Ho et  al., 2011). Patch-clamp measurements of rat brain slices containing PAG
neurons were used to study the mechanism of orexin-A -induced antinociception.
Orexin-A depressed GABAergic inhibitory postsynaptic currents, and the effect was
blocked by SB334867, but also by AM-251, the DAGL inhibitor THL, and the PLC
inhibitor U73122. The effect of orexin-A was mimicked by WIN55,212-2, and the
MAGL inhibitor URB602 enhanced the effect. Therefore, it seems that orexins
mediate their antinociceptive effect in the rat ventrolateral PAG by evoking
production of 2-AG, which acts as a retrograde messenger inhibiting GABA release
from nearby neurons. By this mechanism, orexin-A causes disinhibition in the
ventrolateral PAG, thus allowing initiation of the descending pain inhibition.
Behavioral data were also collected to support this hypothesis. Orexin-A was shown
to reduce hot-plate nociceptive responses in rats when injected into the ventrolateral
PAG, and both SB334867 and AM-251 blocked this effect to a similar extent (Ho et
al., 2011).
Cristino et al. (2013) investigated obesity-associated changes in the neural
circuits of the LH. The studies employed leptin-knockout ob/ob mice  and  normal
mice made obese with a high-fat diet. In lean mice, orexin neurons were mostly
innervated by glutamatergic neurons, as also reported previously (Huang et al., 2007).
However, in ob/ob mice, as well as in mice made obese by a high-fat diet, orexin
neurons were mostly innervated by GABAergic neurons, implying synaptic
remodeling. This would explain the switch of retrograde endocannabinoid signaling
from orexin neurons from inhibition of excitation to inhibition of inhibition, the end
result now being further excitation of orexin neurons when inhibition would be
needed. This, then, would lead to overeating. In this study, the mechanism of this
synaptic remodeling was also investigated. The cause for this change was the lack of
leptin signaling in the ARN, from where most of the neurons that innervate orexin
neurons originate. The ob/ob mice lacked endogenous leptin altogether, but they
received it from their heterozygous mothers during lactation; therefore, the
remodeling of their synapses only occurred after weaning. The mice made obese by
diet also had deficient leptin signaling in the ARN, because they were leptin-resistant.
Leptin resistance is typical in obesity (Cristino et al., 2013).
2.6.2 Evidence from behavioral experiments
Crespo et al. (2008) studied the interaction of the endocannabinoid and orexin
systems in regulating appetite in rats. They used i.c.v. injections of orexin to pre-fed
rats, and reported a dose-dependent increase in their short-term feeding behavior.
They also tested the effect of the CB1 inverse agonist SR141716 when given alone,
and observed a decrease in feeding behavior. Finally, the combined effect of orexin
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and SR141716 was tested. Intraperitoneal injection of SR141716, ten minutes prior to
i.c.v. orexin injection, blocked orexin-induced feeding already at doses that did not
reduce feeding when used alone (Crespo et al., 2008). Therefore, it can be speculated
that orexins exert their orexic functions via the release of endocannabinoids, and this
is due to direct activation of appetite controlling circuits (for example, by inhibiting
the inhibitory GABAergic neurons), but also by increasing the motivation to feed via
reward circuits. Both orexins and endocannabinoids have been shown to be involved
in both of these functions (see also 2.4.3, 2.4.5, 2.5.2).
Because both orexins and endocannabinoids are involved in reward and
addiction, their crosstalk in the VTA, a central dopaminergic nucleus associated with
reward, was investigated by Taslimi et al. (Taslimi et al., 2011). In this study,
injections of the cholinergic agonist carbachol into the LHA were used to induce CPP
in rats. Injections of SB334867 and AM-251 into the VTA prior to carbachol
treatment inhibited carbachol-induced CPP. However, when applied into the VTA
together,  the  antagonists  did  not  produce  an  additive  effect,  but  inhibited  CPP  to  a
similar degree as when applied alone (Taslimi et  al., 2011). The authors speculated
that there could be cross-talk between these systems in the VTA, and it is indeed a
tempting hypothesis. However, more evidence would be needed to verify this.
2.6.3 Evidence from molecular studies
In addition to the physiological evidence for interactions between the brain
cannabinoid and orexin systems, investigations have also been conducted in
recombinant cells that have supported the idea. Actually, the first study suggesting an
interaction between these systems was carried out with recombinant CHO cells that
expressed both CB1 and  OX1 receptors (Hilairet et al., 2003). The authors reported
potentiation  of  OX1 signaling  to  ERK  when  the  receptors  were  co-expressed.  The
potentiation was attenuated by the CB1 antagonist SR141716 and by pertussis toxin,
indicating a requirement for CB1 signaling. OX1 signaling via Gq was not altered by
SR141716, as assessed by IP production, and ERK activation evoked by the CB1
agonist CP55,940 was similar in CHO cells expressing only CB1 and in cells
expressing both receptors: OX1 did not have an effect on CB1 signaling to ERK. The
authors suggested, based on the co-localization of the receptors, that the potentiation
of OX1 signaling  to  ERK  was  due  to  heteromerization  of  OX1 and  CB1 receptors
(Hilairet et al., 2003).
Other studies have subsequently been performed to examine the
heteromerization of CB1 and  OX1 receptors. Ellis et al. (2006) used HEK-293 cells
expressing OX1 or CB1 receptors, and reported internalization of OX1 receptors upon
orexin-A exposure, whereas CB1 receptors showed spontaneous internalization. When
the receptors were co-expressed, both showed this spontaneous internalization.
SR141716 treatment brought both of the receptors to the cell surface, and also
reduced the potency of OX1 signaling to ERK (Ellis et al., 2006).
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Ward et al. (2011) examined the direct physical interactions of CB1 and OX1
receptors with FRET, biotinylation and co-immunoprecipitation. The formation of
heteromeric and homomeric complexes of the receptors in these test systems was
reported, and it appears that not only dimers, but also larger oligomers such as
tetramers are formed. When expressed alone, CB1 receptors were internalized when
exposed to the agonist WIN55,212-2. When expressed together with OX1, CB1
receptors were also internalized when the cells were exposed to orexin-A, and the
maximally effective orexin-A concentration caused equal CB1 receptor internalization
as WIN55,212-2. Orexin-A was ten times more potent in causing the internalization
of OX1-CB1 heteromeres than of OX1 homomeres, and this was suggested to be due to
higher  affinity  of  orexin-A  to  OX1–CB1 complexes   than  to  OX1–OX1 complexes
(Ward et al., 2011).
Although the reports described above have presented strong evidence of the
formation of heteromeric complexes between OX1 and  CB1 receptors, we wished to
consider an alternative explanation for some of the reported observations. In two
papers included in this thesis we investigated the production of endocannabinoids
upon OX1 stimulation and their  effect  on signaling in cells expressing both OX1 and
CB1 receptors (Paper II, Paper III). The results of these studies are presented in more
detail later (5.2, 5.3, 5.5).
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3. Aims of the study
This thesis concentrates on lipid mediators in OX1 orexin receptor signaling. The aim
of the research was to expand the knowledge on the signaling cascades utilized by
OX1 receptors, and finally also to investigate the interactions between OX1 and CB1
receptors. More specifically, the aims of this thesis research were:
1) To investigate and verify PLD activation in OX1 signaling, and to determine the
signaling cascade leading to this activation.
2) To investigate whether OX1 receptor activation evokes release of
endocannabinoids, thus possibly adding a new lipid mediator to OX1 signaling.
3) To determine whether the released 2-arachidonoylglycerol has paracrine or
autocrine actions, and whether previously reported potentiation of OX1 receptor
signaling upon coexpression with CB1 receptors could be due to the autocrine actions
of released endocannabinoids.
4)  To  examine  the  capacity  of  OX1, CB1,  and  OX2 receptors to form constitutive
homo- and heteromeric complexes.
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4. Materials and methods
4.1 Cell culture (I-IV)
Chinese hamster ovary (CHO) cells were grown in Ham’s F12 culture medium
supplemented with 100 U/ml penicillin, 80 U/ml streptomycin, and 10% fetal calf
serum. Recombinant cell-lines stably expressing OX1 or CB1 receptors were used. For
CHO-hOX1,  400  mg/ml  geneticin,  and  for  CHO-hCB1, 0.25 mg/ml phleomycin was
also included in the culture medium. Neuro-2a-hOX1, PC12-hOX1, and HEK293 cells
were grown in Dulbecco’s Modified Eagle’s medium supplemented with 100 U/ml
penicillin, 80 U/ml streptomycin, and 10% fetal calf serum. The growth medium of
PC12-hOX1 cells  was  also  supplemented  with  5%  horse  serum.  All  cells  were
cultured on plastic cell culture dishes (56 cm2 bottom  area)  in  a  humidified  air-
ventilated incubator with 5% CO2 at 37 °C. Insect Sf9 cells were cultured to produce
baculovirus stocks for transductions. They were grown in suspension in spinner flasks
in Grace’s insect cell medium supplemented with 8% fetal bovine serum, 50 μg/ml
streptomycin, 50 U/ml penicillin, and 0.02% pluronic F68 at 27 °C.
4.2 Transfection and transduction (I-IV)
For the transfections, the cells were cultured on 96-, 48-, 24- or 6-well plates,
depending on the experiment. Transfections were used in all studies (I-IV). The
amount of vector DNA varied according to the size of the culture plate well, but the
ratio of DNA and the FugeneHD transfection reagent was kept constant. For 2 μg
DNA,  5  μl  of  FugeneHD  was  used.  The  amounts  of  FugeneHD  and  DNA  were
linearly related to the number of cells in the wells.
Baculoviral transduction was used for Western blot analysis of ERK
phosphorylation (Paper III), where the expression of both OX1 and CB1 receptors in
the same cells was needed. Baculoviral transduction was chosen because its
transduction efficacy was close to 100%. The baculovirus expression vectors
contained C-terminally GFP-tagged hOX1 or hCB1 receptors,  or only GFP under the
cytomegalovirus promoter. CHO cells were transduced by first centrifuging high-titer
virus stocks, removing their growth medium and resuspending the viruses in Ham’s
F12. This medium was then placed on the cells 24 h before the experiment. For some
experiments, the virus-containing medium was removed from the cells 5 h after
transduction, the cells were washed with PBS, and new medium was added.
4.3 Chemicals
The chemicals used in the experiments are listed in Appendix I (Tables 1 and 2).
45
4.4 Phospholipase D assay (I)
PLD cleaves PC to PA and choline by hydrolysis. Water is normally added (as in each
hydrolysis), but PLD prefers primary alcohols, such as 1-butanol by 1000-fold, if
available. In this reaction, the products are choline and a phosphatidylalcohol instead
of PA. PA can be quickly metabolized, and it is also made by other enzyme cascades,
and  the  PA  level  may  therefore  be  a  poor  measure  of  PLD  activity,  while
phosphatidylalcohol is solely formed by PLD. Phosphatidylalcohols are also dead-end
products, allowing cumulative detection (reviewed in  Morris et al., 1997).
For the PLD assay, cells on 6-well plates were labeled with 14C-oleic acid by
mixing the label in fetal calf serum and adding this to serum-free medium. The
normal cell medium was then replaced with this labeling medium 16 h prior to the
experiment. After labeling, the medium was replaced with normal Ham’s F12, and the
cells  were  allowed  to  settle  for  60  min.  After  this,  the  medium  was  removed  and
replaced by medium containing the tested inhibitors (if used), and the cells were
incubated for a further 30 min (except for GGTI-2133, which was added 16 h prior to
the experiment together with the 14C-oleic acid label). All incubations were carried
out at 37 °C. The preincubation medium (with inhibitors) was then removed and
replaced by the activation medium [Ham’s F12 or Hepes buffered medium (HBM)
with 0.3% (v/v) 1-butanol] containing inhibitors (if used) and stimulators. Cells were
stimulated for 30 min at 37 °C, after which the reaction was terminated by replacing
the medium with 300 μl of ice-cold methanol and placing the plate on ice. The cells
were then scraped off and collected in Eppendorf tubes. The wells were then washed
with another 300 μl of methanol, which was combined in the same tubes with the first
set. Lipids were next extracted from these samples before continuing to TLC
separation (4.7).
4.5 Arachidonic acid and 2-arachidonoylglycerol release (II)
For the measurement of AA and 2-AG release, the cells (CHO-hOX1, neuro-2a-hOX1,
PC12-hOX1, and HEK-293 transiently transfected to express hOX1) were grown on 6-
well plates. Cells were labeled with 14C-AA as described for 14C-oleic acid (4.4) 16 h
prior to the experiment. The experiment was started by washing the cells twice with
HBM supplemented with stripped bovine serum albumin (S-BSA; 2.4 mg/ml). The
cells  were  then  stimulated  with  orexin-A  for  7  min  at  37  °C,  after  which  the
supernatant (1000 μl) was collected in Eppendorf tubes and centrifuged briefly in
order to remove detached cells. Next, 800 μl of the supernatant was collected for lipid
extraction.
4.6 Lipid extraction (I-II)
Lipid  extraction  was  used  in  both  the  PLD assay  and  AA and 2-AG release  assays.
Modified Bligh and Dyer protocols were used (Bligh and Dyer,  1959).  For the PLD
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assay (4.4), the lipids were extracted from the cells, whereas for the AA and 2-AG
release assay (4.5) they were extracted from the supernatant.
4.6.1 Extraction from cells (I)
For the PLD assay, the cells were scraped from the wells into methanol and collected
in Eppendorf tubes in 600 μl of methanol (scraping volume plus washing volume).
Next, 500 μl of chloroform was added to the samples and they were vortex-mixed and
incubated for 15 min at room temperature (RT). After this, 400 μl of water was added
to the samples,  they were vortex-mixed again and centrifuged (5 min, 13500 g,  RT).
The upper phase was then removed and the lower phase containing the lipids was
dried under a stream of nitrogen.
4.6.2 Extraction from supernatant (II)
For the AA and 2-AG release assay, supernatants from the centrifuged samples (800
μl) were collected in Kimax tubes, followed by the addition of 2 ml of methanol and 1
ml of chloroform. The tubes were thoroughly shaken, and 1 ml of water and 1 ml of
chloroform were then added. The tubes were shaken again and then centrifuged (5
min, 500 g, RT). The lower phase was collected and dried under a stream of nitrogen.
4.7 Thin-layer chromatography (I-II)
The dried lipid extracts were dissolved in 19:1 chloroform:methanol (PLD assay) or
pure chloroform (AA and 2AG assay) and small amounts of non-labeled lipid
standards (PtdBut for the PLD assay, and AA and 2-AG for the AA and 2-AG release
assay) were added to the samples or applied separately on the TLC plate. The samples
were applied on TLC plates that had been dried at 110 °C for 1 h. For the PLD assay,
plates were pre-treated with 1% (w/v) K+ oxalate in 2:3 (v/v) methanol:water before
drying. The PLD assay plates were developed in an unlined chromatography chamber
with an organic phase of ethyl acetate:isooctane:acetic acid:water (11:5:2:10). For the
AA and 2-AG release assay, the plates were developed in ethyl acetate:methanol
(90:10) in a chromatography chamber lined with filter paper. An imaging plate (BAS-
MS, Fujifilm, Tokyo, Japan) was exposed overnight with the vacuum-dried TLC
plates. The exposed plate was scanned with a FLA 5100 scanner (Fujifilm) and the
band intensities were quantitated with Nikon NIS-Elements AR (Nikon, Tokyo,
Japan). The amount of the 14C-label in the bands was also measured by scraping off
the bands, humified with water, into scintillation tubes, adding scintillation cocktail
(Hisafe 3, Wallac-PerkinElmer, Turku, Finland), and measuring with a liquid
scintillation counter (Wallac 1414). The bands were identified with the help of the
non-labeled lipid standards made visible on the TLC plate with iodine vapor.
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4.8 3H-overflow from cells labeled with 3H-arachidonic acid and 3H-oleic
acid (II)
In study II, the release of radiolabeled lipid products from cultured cells was first
measured without distinguishing between the different lipid species. This was done by
seeding the cells on 24-well plates and labeling them 16 h prior to the experiment
with either 3H-AA or 3H-OA. The following day, the cells were washed twice with
HBM supplemented with S-BSA (2.4 mg/ml), and then stimulated with orexin-A in
250 μl HBM with S-BSA for 7 min at 37 °C. Next, 200 μl of this stimulation medium
was collected in Eppendorf tubes on ice and centrifuged (1.5 min, 16 000 g, +4 °C).
After this, 100 μl of each sample was transferred into a scintillation tube and counted
(4.7).
4.9 Phospholipase C assay (I-II)
PLC activity was measured by determining the cumulative amount of inositol
phosphates produced in cells upon orexin receptor activation. The cells were grown
on 24-well plates and labeled with 3H-inositol 20 h prior to the experiment by adding
the label into the growth medium. Before the experiment, the cells were washed with
HBM. HBM containing 10 mM LiCl (inhibitor of inositol monophosphatase) was
added and the cells were incubated at 37 °C for 10 min. After this, the cells were
stimulated with orexin-A for another 20-30 min at 37 °C. The reactions were stopped
by rapidly replacing the medium with 200 μl of 0.4 M ice-cold perchloric acid,
followed by freezing of the plate. After thawing of the samples, 100 μl of neutralizing
medium (0.36 M KOH, 0.3 M KHCO3) was added, and the insoluble fragments were
spun down (10 min, 1100 g, +4 °C). Anion-exchange chromatography was used to
isolate inositol phosphates from the supernatant. The amount of inositol phosphates
was determined by liquid scintillation counting (4.7).
4.10 Adenylyl cyclase assay (I-II)
AC activity  was  determined  in  papers  I,  II  and  III  in  different  formats  (96-  and  24-
well plates) and with some variation with regard to the amounts of inhibitor or
activation solutions and activation times. Therefore, the method is presented here
without these details. Cells were labeled with 3H-adenosine 2 h prior to the
experiment, washed with PBS, and incubated in Ham’s F12 containing 500 μM
IBMX (1-methyl-3-isobutylxanthine, an inhibitor of cyclic nucleotide
phosphodiesterase) for 10 min at  37 °C. Activators were then added for 10 min. The
reaction was stopped by replacing the activation medium with 0.33 M perchloric acid
and freezing the cells. The thawed samples were centrifuged (10 min, 1100 g, RT)
and the supernatants were placed in chromatography columns to separate the 3H-
ATP+3H-ADP from 3H-cAMP fractions with sequential Dowex/alumina
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chromatography. The amount of radioactivity in the fractions was determined by
liquid scintillation counting (4.7).
4.11 Ca2+ measurements (II)
For Ca2+ measurements, the cells were grown on glass coverslips coated with
polyethylene imine to reduce detachment of the cells during the experiment. The cells
were loaded with the Ca2+ indicator fura-2 acetoxymethyl ester (4 μM) in HBM with
1 mM probenecid for 20 min at 37 °C. The coverslips were then rinsed with HBM and
placed into an imaging chamber with constant perfusion at 35 °C. When inhibitors
were used, the cells were pre-incubated with them, and the inhibitors were also
included in the perfusion medium throughout the experiment. Ca2+ responses were
measured by exciting the cells with light rapidly alternating between 340 and 380 nm
and collecting the emitted light through a 400-nm dichroic mirror and a 450-nm long-
pass filter. The measurements were performed with a Nikon TE 2000 fluorescence
microscope and an Andor iXon 885 electron-multiplying charge-coupled device (EM-
CCD) camera under the control of Nikon NIS-Elements software.
4.12 ERK phosphorylation assay (III)
Cho-hCB1 cells were grown on 6-well plates and transduced with recombinant
baculovirus vectors with hOX1-GFP or only GFP (negative control). Five hours later,
the virus-containing transduction medium was removed, cells were washed with PBS
and left overnight in serum-free Ham’s F12 medium. Inhibitors were added to the
cells in the serum-free medium 30 min prior to stimulation. The cells were stimulated
with  orexin-A or  HU210 for  10  min  and  then  washed  with  ice-cold  PBS on  ice  and
rapidly lysed with 100 μl of lysis buffer [50 mM Hepes, 150 mM NaCl (pH 7.5) + 10
% (v/v) glycerol, 1 % (v/v) Triton X-100, 1.5 mM MgCl2, 1 mM EDTA, 10 mM Na1-
pyrophosphate,  1  mM  Na1-orthovanadate, 10 mM NaF, 250 mM p-nitrophenol
phosphate, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mM phenylmethylsulfonyl
fluoride, and PhosSTOP phosphatase inhibitor cocktail (Roche)]. The samples were
collected in Eppendorf tubes, briefly centrifuged (2 min, 13 500 g, RT) and the
supernatant was collected. From the supernatant, a sample with 10 μg of protein was
collected, boiled in Laemmli buffer, and separated on a 10% sodium dodecyl sulfate
(SDS) polyacrylamide gel by electrophoresis. After separation, the proteins were
transferred from the gel to a nitrocellulose membrane. The membrane was then
washed with PBS and blocked with Odyssey blocking buffer (LI-COR bioscience,
Lincoln, NE, USA):PBS (50:50) for 1 h. After blocking, the membrane was incubated
with primary antibodies [rabbit anti-active MAPK IgG (Promega) and mouse p44/42
MAPK (ERK1/2) IgG (Cell Signaling Technology, Danvers, MA) in a 50:50 mixture
of Odyssey blocking buffer and PBS] overnight at 4 °C with gentle shaking. On the
next day, the membrane was washed with PBS (3 times 10 min) and incubated with
secondary antibodies (in a 50:50 mixture of Odyssey blocking buffer and PBS) for 60
min at RT, protected from light. The secondary antibodies were Dylight 800-
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conjugated goat anti-rabbit IgG and 680-conjugated goat anti-mouse IgG antibodies
(LI-COR). After the incubation, the membrane was kept protected from light and
washed with PBS (3 times 10 min). The bands from the membrane were then detected
with  an  Odyssey  Infrared  Imaging  system  (LI-COR)  and  the  band  intensities  were
quantitated with Nikon NIS-Elements software.
4.13 Luciferase assay (III)
The activation of ERK can be detected by following it downstream to the
transcription factor Elk-1. The pSG-GalElk-1 plasmid codes for a fusion protein of
the DNA-binding domain of the yeast transcription factor Gal4 and the transactivation
domain of Elk-1 (Kortenjann M, 1994). In our ERK luciferase assay, this fusion
plasmid was transfected to the cells together with pGL3 G5 E4 Δ38, which contains
five binding domains for Gal4 that control the expression of firefly luciferase
(Kamano et  al., 1995). When ERK is activated, it phosphorylates Elk-1, which then
leads to the expression of firefly luciferase. Firefly luciferase activity is measured to
determine the activity of ERK. The cells are also transfected with the pRL-TK
plasmid, which contains Renilla reniformis luciferase under the control of thymidine
kinase promoter from herpes simplex virus. Renilla luciferase activity is used for
normalizing the firefly luciferase signal.
The cells were grown on 96-well plates, transfected with the plasmids
described above, accompanied with receptor plasmids for hOX1, hCB1 or  M1.  If  no
receptor plasmids were used, an empty vector was used to keep the DNA amounts
equal. Five hours after the transfection, the cells were washed with phosphate
buffered saline (PBS) and left in serum-free medium overnight. On the following day,
inhibitors were added in serum-free medium, and the cells were stimulated 30 min
later  with  orexin-A,  HU210  or  2-AG  for  5  h.  After  the  stimulation,  the  cells  were
lysed with Passive Lysis Buffer (from the Dual Luciferase Assay Kit; Promega) for
15 min, and the samples were collected and briefly centrifuged. The luminescence
from both luciferases (activated by adding their substrates; Dual Luciferase Assay
Kit) was sequentially measured from the supernatants with a Glomax 20/20
luminometer (Promega) according to the manufacturer's instructions.
4.14 Cell–cell communication assay (II-III)
The capacity of the 2-AG released after OX1 activation to activate nearby cells
expressing CB1 receptors was investigated in papers II and III by two different means
(Figure 5). Modulation of AC activity and activation of Elk-1 were measured in an
artificial cell–cell communication assay.
CB1 receptors couple to Gi proteins, which inhibit AC activity and therefore
cAMP production. In the reporter assay, CHO-hCB1 cells were labeled with 3H-
adenosine  for  2  h,  washed  with  PBS  and  detached  with  PBS  containing  EDTA.
Detached cells were spun down and resuspended in Ham's F12 medium containing
500 μM IBMX. After 10 min of incubation at 37 °C, the cells were placed on top of
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CHO-hOX1 cells grown on a 24-well plate. The plates were then gently centrifuged (3
min,  100  g,  RT)  and  were  left  at  37  °C  for  10  min  to  settle.  The  cells  were  then
stimulated with forskolin combined with orexin-A and HU210 for 7 min. The rest of
the experiment was performed as described for the AC assay (4.10).  In  this
experiment, the measured cAMP signal came from the CHO-hCB1 cells, because only
these were labeled with tritium.
A  similar  principle  was  used  in  studying  Elk1  activation.  CHO-hCB1 cells
were transfected as described previously for the luciferase assay. Five hours after the
transfection, CHO-hCB1 cells were detached and mixed with detached CHO-hOX1
cells.  Both cell  types were then plated on a 24-well  plate in normal growth medium.
About 24 h after plating the cells, the medium was replaced with serum-free medium
and the cells were serum-starved overnight. The following day, the cells were treated
as described for the luciferase assay (4.13).
Figure 5. A schematic illustration of the cell–cell communication assay. OX1
activation-induced release of 2-arachidonoylglycerol (2-AG) leads to activation of
CB1 receptors  in  the  neighboring  cells.  Activated  CB1 receptors then modulate
adenylyl cyclase (AC) activity (A) and activate the extracellular signal-regulated
kinase (ERK) pathway (B). ATP, adenosine triphosphate; cAMP, cyclic adenosine
monophosphate; DAGL, diacylglycerol lipase; FF luc, firefly luciferase; GalElk1,
fusion plasmid of Gal4 and Elk1 transcription factor; pGL3, plasmid with Gal4
binding sites, controls FF luc expression.
4.15 Receptor binding
Expression levels of recombinant receptors were determined with radioligand binding
assays. 125I-orexin-A was used for OX1 receptors and 3H-SR141716 for CB1
receptors. For OX1 expression studies, CHO-hOX1 cells (transfected with constructs
used in the Elk-1 luciferase assay) or CHO-hCB1 cells transfected with OX1 (and
constructs used in the Elk-1 luciferase assay to make the results comparable) were
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used. Twenty-four hours after the transfection, the cells were detached, spun down,
and resuspended in HBM containing 0.1% (w/v) S-BSA. The cells were then placed
in low-protein-binding Eppendorf tubes with 125I-orexin-A for 10 min. Nonspecific
binding was determined by preincubating the cells with 10 μM SB-334867 before
adding 125I-orexin-A. The cells were then rapidly spun down (30 s, 14 000 g, +2 °C),
the pellet was washed superficially with ice-cold HBM and then resuspended in
HBM, and the radioactivity measured with a Wallac Wizard 1480 gamma counter. To
determine the expression levels of CB1 receptors, the cells were plated on 48-well
plates coated with polyethylene imine. Similar transfections as for OX1 expression
studies were carried out, and the cells were used 24 h after transfection. The cells
were washed with HBM, and incubated in HBM containing 0.1 % (w/v) S-BSA and
3H-SR141716. The nonspecific binding was determined with 10 μM HU210. After a
60-min incubation at RT, the plate was placed on ice and the cells were washed twice
with ice-cold HBM. The cells were then lysed with NaOH and collected in
scintillation tubes for scintillation counting (4.7).
4.16 Bioluminescence resonance energy transfer (BRET2) assay (IV)
Dimerization of OX1, OX2 and CB1 receptors was studied using the bioluminescence
resonance energy transfer (BRET2) method. In this method, cells are transfected with
fusion constructs of Renilla luciferase (Rluc) or green fluorescent protein 2 (GFP2)
and the receptors of interest. When a receptor tagged with Rluc comes in close
proximity  to  a  GFP2-tagged receptor, and a substrate for Rluc is present, the light
energy of Rluc may excite the nearby GFP2, producing a signal. These signals can be
measured, and the specific GFP2 signal divided by the specific luminescence is called
the BRET ratio. CHO control cells were grown on 6-well plates and transfected with
different  ratios  of  the  two  constructs.  The  amount  of  Rluc  construct  DNA  was  kept
constant, while GFP2 was varied. An empty vector was used to keep the total amount
of  DNA  constant.  After  24  h,  the  cells  were  detached  with  PBS  containing  EDTA,
spun down and resuspended in HBM. The cell suspensions were dispensed on white
384-well plates and the plates placed in a Pherastar FS instrument (BMG, Labtech
Gmbh). The measurements were performed at RT, using the BRET2 optic module.
Renilla luciferase substrate coelenterazine 400a was added to the cells in a 5 μM final
concentration with an automated dispenser.
4.17 Data analysis and statistical procedures (I-IV)
The results are presented as mean ± S.E.M.; N refers to the number of batches of
cells. The number of parallel samples differed between experiments. In WB (III) and
TLC  (II)  experiments,  it  was  two,  and  in  AC,  PLC  (I-II)  and  the  luciferase  assay
experiments (III), it was three or four. 3H-overflow experiments (II) were conducted
with  six  and  Ca2+-imaging experiments (II) with 30 or more parallel samples. Each
experiment was repeated at least three times.
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All pairwise comparisons were carried out with Student’s paired or non-paired
two-tailed t-tests with Bonferroni’s correction (I–IV), except for the Ca2+-imaging
experiments (II), where the χ2 test was used for corresponding cell counts. The F-test
was used when comparing different models for concentration–response curves (I).
Statistical significance is indicated as follows: ns (not significant), *P < 0.05, **P <
0.01, ***P < 0.001.
Nonlinear curve-fitting and determination of EC50 values were performed with
Microsoft Excel (I–III).
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5. Results and Discussion
5.1 Phospholipase D activation (Paper I)
There has been indirect evidence for PLD action upon OX1 receptor activation
(Johansson et al.,  2008).  In paper I,  we utilized the PtdBut generation assay (4.4) to
directly show that PLD is potently activated upon OX1 receptor stimulation. Orexin-A
was a 10 times more potent activator than orexin-B, as expected for OX1.
With  the  help  of  PLD1  and  PLD2  inhibitors,  we  determined  that  the  PLD
isoform responsible for PtdBut generation was PLD1. The employed PLD2 inhibitor
also  showed  some  inhibition  of  the  PtdBut  response  when  used  at  a  high
concentration  (1  μM).  This  inhibition  was  stronger  for  100  nM  orexin-A  than  for  1
nM. At high orexin concentrations, PLD1 activation would produce significant
amounts of PA, leading to the activation of PIP5K, and an increased amount of PIP2.
PIP2 would then activate PLD2, offering an explanation for the finding. However,
high concentrations of the PLD2 inhibitor also inhibit PLD1 activity (Scott  et al.,
2009), and thus the finding may also be due to PLD1 inhibition.
 Next, we aimed to determine what lies upstream of PLD1 activation. PLD1
can be activated by various factors. PIP2 increases the activity of both PLD1 and
PLD2, but more importantly, it is required for their membrane localization and as a
cofactor (Brown et  al., 1993; Liscovitch et al., 1994). PA, the product of PLD1, can
activate PIP5K, which leads to PIP2 production  and  therefore  creates  a  positive
feedback loop (Jenkins et al., 1994). Many other factors regulate PLD activation. As
described in 2.3.4,  various PKC subtypes and small  G-proteins of the ARF and Rho
families can activate PLD1 (Henage et al., 2006). In previous studies, OX1 receptors
in  CHO  cells  have  been  shown  to  utilize  nPKC  but  not  cPKC  for  signaling  to  AC
(Holmqvist et al., 2005). Of the nPKC isoforms, CHO cells were reported to express
PKCε and -δ, (Hill et al., 2003; Holmqvist et al., 2005), and to be able to activate both
of them, as assessed from the translocation of recombinant isoforms (Holmqvist et al.,
2005). Holmqvist et al. (2005) suggested, however, that the isoform utilized in
signaling  to  AC  was  PKCδ,  but  not  PKCε.  Direct  activation  of  PKC  (likely  both
conventional and novel isoforms) with 12-O-tetradecanoylphorbol-13-acetate (TPA)
strongly activated PLD1 in CHO cells. We therefore used inhibitors of PKC
subclasses  to  determine  whether  PKC  was  also  involved  in  OX1 signaling  to  PLD.
Gö6976 (an inhibitor of cPKCs and PKD) and GF109203X (an inhibitor of both novel
and classical PKCs) were used, but only GF109203X showed potent inhibition of
both TPA and orexin responses, while Gö6976 showed only very weak inhibition
when used at a high concentration (10 μM).
We further studied the involvement of different PKC subclasses in PLD
activation in CHO cells. For this, we utilized small peptide activators and inhibitors.
For PKC regulation, these peptides utilize the PKC-binding domains of receptors for
activated C kinase (RACKs). In some systems, the membrane permeation peptides
alone  have  been  reported  to  inhibit  the  action  of  PKC  and  PKA  (Ekokoski et al.,
54
2010), but we did not observe this effect. An activator of cPKC (KAC1-1) did not
produce any PLD stimulation, while activators of PKCε (KAE1-1) and PKCδ (KAD1-
1) activated PLD. Furthermore, the activity produced by KAE1-1 could be abolished
by an inhibitor of PKCε (KIE1-1),  which had no effect,  however,  on PLD activation
induced  by  orexin-A  or  TPA.  Thus,  PKCδ emerged  as  the  more  interesting  of  the
nPKC isoforms. Unfortunately, a specific peptide inhibitor of PKCδ was not
commercially available. Consequently, we used rottlerin as a PKCδ inhibitor,
although  we  were  aware  that  it  is  not  a  very  selective  or  good  inhibitor  (Soltoff,
2007). Rottlerin produced a clear concentration-dependent inhibition of PLD
activation, supporting the notion that PLD was activated by PKCδ.
Gö6976 also inhibits PKD, and according to one study, PKD1 and PKD3 are
activated by OX1 (Peltonen et al., 2010). We tested with dominant-negative PKD
constructs whether the small amount of inhibition by Gö6976 could be due to
inhibition of PKD, but the dominant-negative constructs had no effect on PLD
activation.
Small G-proteins of the Rho family can activate PLD1 (reviewed in Frohman
et al.,  1999).  Furthermore,  many  GPCRs,  for  example  the  M3 muscarinic
acetylcholine receptor, utilize Rho-family G-proteins to activate PLD (Schmidt et al.,
1996). Therefore, we tested whether inhibition of geranylgeranyl transferase with
GGTI-2133, and subsequently the maturation and attachment of Rho family G-
proteins to the cell membrane, would have an effect on OX1 receptor-mediated PLD
activation. The cells were incubated with GGTI-2133 24 h prior to the experiment to
inhibit the isoprenylation of Rho family G-proteins in the early phase. Clear changes
in the shape of the cells were observed after 24 h, indicating an effect by the inhibitor.
Due to concerns about cell viability with longer incubations, the incubation time was
kept at 24 h. No effect on PLD activity upon OX1 stimulation was seen with a 100 nM
concentration of GGTI-2133. A concentration of 1 μM tended to evoke some,
statistically non-significant inhibition, but to be certain that these G-proteins were not
involved, we utilized more specific inhibitor constructs of Rho family G-proteins.
None of these constructs showed any inhibition of the PLD response. Rho family G-
proteins do not therefore appear to be involved in OX1 receptor-induced PLD
activation.
A major question is how the nPKC/PKCδ activation by orexin receptors takes
place. nPKCs are Ca2+-insensitive, but are instead activated by DAG and
phosphorylation of either serine/threonine or tyrosine residues (reviewed in Zhao et
al., 2012). An additional means of activating PKCδ is proteolytic cleavage by
caspase-3, but this is mainly associated with apoptosis (Ghayur et al., 1996; reviewed
in Zhao et al., 2012). We aimed to test whether other OX1 signaling pathways, such as
PLC or PLA2, were involved in activating PLD. Both of these pathways could
activate  PKC,  PLC  by  producing  DAG  and  PLA2 by producing AA (Shirai et al.,
1998). U-73122 was used to inhibit PLC and methyl arachidonyl fluorophosphonate
(MAFP)  to  inhibit  PLA2,  but  neither  of  them  had  any  effect  on  PLD  activation  by
orexin-A. Therefore, the nPKC activation occurs via some other pathway. As
mentioned above, PKCδ is activated by phosphorylation of many sites, including
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various tyrosine residues (reviewed in Steinberg, 2004). Kinases involved in this
include Src family kinases, and OX1 receptors have been suggested to activate them
(Ammoun et al., 2006a; Voisin et al., 2008). This could be one possible pathway for
OX1 receptors to activate PKCδ, but it has not yet been demonstrated.
Rhodopsin  family  GPCRs,  such  as  M3 muscarinic, H1 histamine,  and  B2
bradykinin receptors, have been reported to activate PLD via Rho and Arf family G-
proteins in 1321N1 human astrocytoma cells (Rumenapp et al., 1995; Schmidt et al.,
1996; Mitchell et al., 1998). As mentioned in 2.2.2, OX1 receptors also belong to the
rhodopsin family of GPCRs, and like M3 are strongly Gq-coupled, even though OX1
can also couple to other heterotrimeric G-proteins. It is therefore rather interesting
that while M3 activates PLD via Rho and Arf, these small G-proteins do not appear to
be involved in the OX1-mediated activation of PLD. In one study, it was reported that
M3 receptors activated PLD via R-Ras in HEK-293 cells, and that the R-Ras
activation was driven by cAMP via EPAC (Lopez De Jesus et  al., 2006). We tested
the effect of increasing cAMP levels by activating AC with forskolin, but it had no
effect on PLD; therefore, it appears that this mechanism is not involved in OX1-
mediated PLD activation in CHO cells. OX1 receptors also only activate AC at such
high orexin concentrations that involvement of cAMP would not have been plausible
here. OX1 receptors differ from the GPCRs mentioned above, because PLD activation
appears to solely rely on PKCδ, while other GPCRs often utilize multiple pathways to
activate PLD. These experiments have, however, been performed in different types of
host  cells,  which  probably  also  affects  the  signaling.  The  signaling  of  OX1 receptors
can vary according to the cells type, as is seen, for example, in Paper II, for 2-AG and
AA production (5.2).
OX1 receptors potently activate PLD, i.e. in the same orexin-A concentration
range as PLC in CHO cells, but the physiological significance of this activation is not
clear. PA, the product of PLD activity, is a potent lipid messenger and also easily
converted into other potent messengers, DAG or LPA. These lipids have a plethora of
targets in cells. Probably one of the best studied PA targets is the mammalian target of
the rapamycin (mTOR) complex, which is stabilized by PA, (reviewed in Foster,
2009). This complex is known to be anti-apoptotic and to promote cell survival and
proliferation. Orexin-A has been shown to induce apoptosis (Rouet-Benzineb et al.,
2004; Ammoun et al., 2006b), but also to enhance the proliferation of neurons in the
dentate gyrus (Ito et al., 2008) and 3T3-L1 preadipocytes (Skrzypski et al., 2012). In
3T3-L1 preadipocytes, this proliferative effect was mediated by ERK signaling, but
the activation of mTOR following orexin-A exposure has not been studied. Therefore,
it would be interesting to investigate whether mTOR complexes are activated upon
OX1 activation, and whether they are involved in orexin-A-mediated cell
proliferation.
In summary, OX1 potently activates PLD1 in CHO cells. This solely relies on
an  nPKC,  probably  PKCδ (Figure  6).  The  activation  mechanism  of  this  PKC  is
unclear, but it (or PLD) does not require AC, PLC, PLA2, Rho family GTPase, Gβγ,
or PKD activity. The physiological significance of OX1 signaling to PLD has not yet
been investigated.
56
Figure 6. Investigated pathways for OX1 induced phospholipase D (PLD) activation.
Crosses on top of the arrows indicate that the pathway is not involved in OX1 induced
activation of PLD. AC, adenylyl cyclase; DAG, diacylglycerol; PKCδ, protein kinase
Cδ; PKD, protein kinase D; PLC, phospholipase C; PLD, phospholipase D.
5.2 AA and 2-AG release (Paper II)
Turunen et al. (2010) reported that when 3H-AA-labeled CHO-hOX1 cells were
stimulated with orexin-A, abundant release of the 3H-label into the medium was
observed. This indicates the activation of a lipid-signaling cascade, which was
interpreted as PLA2 activity. However, the identity of the released lipid (or other
molecular) species was not determined. In Paper II, we examined this issue further
with more selective pharmacological inhibitors and by determining the identity of the
released lipid species.
TLC separation of the lipid species released from 14C-AA-labeled cells
revealed two prominent 14C-labeled bands, which migrated at the same speed as non-
labeled reference standards of AA and 2-AG. There is one pathway mainly
responsible for 2-AG production, as described in 2.3.4, and it includes PLC and
DAGL. PLA2 activation, on the other hand, is known to lead to AA release, and this
pathway was probably also involved here. Indeed, when applied together, the
inhibitors of DAGL and cPLA2α/ζ, THL (Bisogno et  al., 2006) and pyrrophenone
(PP) (Seno et  al., 2000; Ghomashchi et al., 2001), fully blocked the release of both
AA and 2-AG. THL alone entirely abolished the 2-AG release, but also a part of the
AA  release.  PP  inhibited  a  part  of  the  AA  release,  while  it  had  no  effect  on  2-AG
release.  We  thus  concluded  that  2-AG  release  was  solely  dependent  on  DAGL
activation, while both AA produced by cPLA2α or ζ activity and AA formed by
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hydrolysis of 2-AG contributed to the observed release of AA (Figure 7). We utilized
these inhibitors in the previously used "3H-overflow" method (4.8)(Turunen et al.,
2010), and observed that the release of the 3H-label was completely abolished by co-
application of THL and PP. Upon analysis of the concentration–response curves of
orexin-A and  the  impacts  of  the  inhibitors,  in  both  TLC separation  and 3H-overflow
experiments, it appears that cPLA2 (pEC50 ≈ 9.3 from 3H-overflow, and pEC50 ≈ 9.8
from TLC separation) is activated more potently than DAGL (pEC50 ≈ 8.4 from 3H-
overflow, and pEC50 ≈ 8.3 from TLC separation).
Figure 7. Pathways producing arachidonic acid (AA) upon activation of OX1 orexin
receptors by orexin-A in recombinant CHO-hOX1 cells.  2-AG,  2-
arachidonoylglycerol; cPLA2, Ca2+-dependent/cytosolic phospholipase A2; DAGL,
diacylglycerol lipase; MAGL, monoacylglycerol lipase.
DAG, the substrate of DAGL, can be derived from either PLC action or from
PLD-produced PA. The concentration–response curves for PLD1 and PLC are very
similar (Paper I, Figure 8), and this does not therefore suggest either pathway.
Therefore, we utilized a PLD1 inhibitor and the PLC inhibitor U73122 to determine
which of these enzymes is involved. The PLD1 inhibitor showed only minor
inhibition of 3H-overflow, while PLC inhibition blocked it completely. Unfortunately,
the PLC inhibitor U73122 is not very specific (Taylor and Broad, 1998), but no better
alternatives are available for inhibiting PLC. However, the PLD1 inhibitor used is
both specific and potent (Paper I), and thus it appears reliable to conclude that the
PLC pathway is the one producing DAG in this case.  This is  also reported to be the
pathway producing 2-AG in the ventrolateral PAG of the rat brain (Ho et al., 2011).
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When CHO cells were labeled with 3H-oleic acid instead of 3H-AA, the 3H-
overflow induced by OX1 activation  was  much  smaller  and  less  potent.  PP  had  no
effect on this 3H-overflow, while THL inhibited it completely. The enzyme
responsible for the effect in 3H-OA-labeled cells therefore appears to be DAGL, while
cPLA2 is not involved. This would suggest that the cPLA2 species involved in AA
release is cPLA2α and not cPLA2ζ, as the α isoform is highly AA-specific (reviewed
in Ghosh et al., 2006). Oleic acid may also mostly end up in the sn1 position  of  a
phospholipid and might not therefore be released by cPLA2, which mostly acts on
fatty acids in the sn2 position (reviewed in Ghosh et al., 2006).
We  also  studied  OX1 activation in more neuron-like cells: neuro-2a-hOX1,
PC12-hOX1, and HEK293 cells. In neuro-2a and HEK-293 cells, stimulation with 100
nM orexin-A induced the release of 2-AG and AA. In these cells,  unlike CHO cells,
the release of both AA and 2-AG was fully blocked with THL, indicating that the AA
released from these cells was the product of 2-AG hydrolysis, and not of cPLA2
activity. In PC-12 cells, we could not see any response to orexin-A, but this may have
been  masked  by  strong  basal  release  of  AA and 2-AG.  It  appears  that  the  ability  of
OX1 receptors to evoke 2-AG release is dependent on the cell type, as is AA release.
The 2-AG release is, however, a signaling pathway also utilized by other cell types
besides CHO cells.
Figure 8. Activation  of  PLD  and  PLC.  PLD  activation  is  depicted  by  PtdBut
generation,  and  PLC  by  IP  production.  Both  enzymes  are  activated  in  the  same
orexin-A concentration range. Redrawn from Paper I.
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Figure 9. Pathway producing 2-arachidonoylglycerol (2-AG) upon OX1 activation.
Diacylglycerol (DAG) for 2-AG production comes solely from the action of
phospholipase C.
5.3 Cellular actions of 2-AG from orexin receptor signaling
5.3.1 Paracrine signaling (Papers II and III)
We managed to show in Paper II that 2-AG was released into the extracellular
medium from CHO-hOX1 cells upon OX1 stimulation. 2-AG should be able to act on
CB1 receptors, and we next wanted to examine whether this would occur in the
classical paracrine manner (2.5.1)  in our test  system. For this purpose,  we devised a
cell–cell communication assay (4.14), modified from a method used to study nitric
oxide production upon muscarinic receptor stimulation (Hu and el-Fakahany, 1993).
We used CHO-hCB1 cells  to  measure  2-AG  release  from  CHO-hOX1 cells by
assessing the AC activity in CHO-hCB1 cells. We first verified the ability of direct
CB1 stimulation to affect AC activity in CHO-hCB1 cells. Exogenous 2-AG (and the
synthetic agonist HU210) strongly and concentration-dependently inhibited AC
activity (Paper II), as expected based on previous knowledge (Howlett, 1984). The
effect was fully blocked by AM-251, verifying that the effect was solely mediated by
CB1 receptors.
We thus proceeded with the cell–cell communication assay. Briefly, the CHO-
hCB1 cells  were  labeled  with 3H-adenine and plated together with CHO-hOX1 cells.
The cells were then stimulated with forskolin and orexin-A, and the cAMP responses
were measured. Only the CHO-hCB1 cells were labeled, and the responses measured
would therefore solely originate from them. Orexin-A caused a clear concentration-
dependent decrease in cAMP production in forskolin-stimulated CHO-hCB1 cells
(Paper II). The orexin-A-induced decrease in cAMP formation was inhibited by the
OX1 antagonist SB334867, the CB1 antagonist/inverse agonist AM-251, and THL,
which inhibits 2-AG production (Figure 10). This implies that the orexin-A-induced
decrease in cAMP in CHO-hCB1 cells is mediated by the OX1 receptor-induced
release of 2-AG from CHO-hOX1 cells,  which  then  acts  on  CB1 receptors in
neighboring CHO-hCB1 cells (Figure 10). This fits the scheme of retrograde synaptic
transmission, where the postsynaptic cell releases 2-AG, which then diffuses to the
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presynaptic cell and acts on CB1 receptors (reviewed in Kano et al., 2009). The
mechanism by which 2-AG exits the cells is debated, but there is some evidence for a
transporter (Chicca et al.,  2012).  If  there  is  a  transporter,  its  expression  or  absence
from different cell types might also partly explain why 2-AG release is not seen in all
cell types, such as PC-12-hOX1, and why it is released with different potencies.
Both OX1 and CB1 receptors are also coupled to ERK activation in CHO cells,
as seen in both the phosphorylation of ERK and downstream ERK activity by
activation of the transcription factor Elk-1 (Bouaboula et al., 1995; Ammoun et al.,
2003) (Paper III). We utilized a similar cell–cell communication assay (4.14) to
explore paracrine 2-AG activity by measuring the Elk-1 activity in CHO-hCB1 cells
upon orexin stimulation of CHO-hOX1 cells (Paper III). Orexin-A stimulated Elk-1
activity in a THL- and AM-251-sensitive manner (Paper III), similar to the AC assay
(Paper II).
Figure 10. The sites of action of the inhibitors used in the cell–cell communication
assay.  A  cell  expressing  OX1 receptors is depicted on the left and a cell with CB1
receptors on the right. 2-AG produced by OX1 expressing cell crosses the space
between  the  cells  and  binds  to  CB1 receptor of the other cell. AM-251, CB1
antagonist/inverse agonist; 2-AG, 2-arachidonoylglycerol; DAGL, diacylglycerol
lipase; SB334867, OX1 antagonist; THL, diacylglycerol lipase inhibitor.
5.3.2 Autocrine signaling
It  was  previously  shown  that  co-expression  of  OX1 and  CB1 receptors strongly
potentiates OX1 receptor signaling to ERK in CHO cells, and less prominently also in
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HEK-293 cells (2.6)(Hilairet et  al., 2003; Ellis et al., 2006). While the rather
convincing results presented in these studies do not directly imply that these receptors
are capable of forming heteromeric complexes, the production of 2-AG in these
systems was not taken into account. Therefore, we aimed to investigate whether the
potentiation of ERK signaling could be explained by the autocrine action of released
2-AG (Paper III).
We started by studying the potentiation of ERK phosphorylation in CHO-
hCB1 cells  transduced  to  also  express  OX1 receptors. When the cells with both
receptors were activated with orexin-A, a strong ERK response was seen. The
response was antagonized (EC50 shifted more than 100-fold) by the CB1 antagonist
SR141716. This is in line with the observations of Hilairet et al. (2003). Inhibition of
the  production  of  2-AG  with  THL,  however,  produced  similar  attenuation  of  the
potentiation as SR141716, indicating that the potentiation requires DAGL activity,
and thus is probably mediated by 2-AG acting on CB1 receptors.  As  both  OX1 and
CB1 receptors are known to activate ERK (2.3.3, 2.5.1, Paper III), it appears logical
that when both of these receptors are activated, there is more signaling to ERK, and
therefore potentiated ERK phosphorylation, especially as the receptors are likely to
utilize different signaling pathways due to their different G-protein coupling (2.2.2,
2.5.1). Our results imply that the released 2-AG can explain the potentiation of ERK
signaling, and no receptor heteromerization is necessary.
The activity of ERK itself was studied utilizing an Elk-1-driven reporter assay
(4.13). The results of these experiments supported the idea that the potentiation of
ERK was due to the autocrine action of released 2-AG. In these experiments, we
utilized AM-251 as a CB1 antagonist, instead of SR141716, as an additional control.
THL and AM-251 attenuated the potentiation of Elk-1 signaling in cells expressing
both OX1- and CB1-receptors to a level similar with the control cells expressing only
OX1.  The  potentiation  of  Elk-1  activity  was  not  as  strong  as  that  of  ERK
phosphorylation; the EC50 values were shifted less than 10-fold when the receptors
were co-expressed, compared to cells expressing only OX1. Elk-1 activity was,
however, measured after 5 hours of cumulative stimulation, while for ERK
phosphorylation the stimulation time was only 10 min and the response is not
cumulative. During the 5 hour stimulation, some of the phosphorylated ERK could
well have undergone dephosphorylation before activating Elk-1, whereas during 10
min of activation, rapid phosphorylation of ERK was seen, but not the situation after
the phosphorylation ceases. In addition, not all phosphorylated ERK targets Elk-1, but
also other transcription factors (reviewed in Chang et al.,  2003),  and  some  of  the
phosphorylated  ERK remains  in  the  cytoplasm and  does  not  enter  the  nucleus  at  all
(reviewed in Mebratu and Tesfaigzi, 2009). The phosphorylated ERK that targets
transcription factors other than Elk-1, and also ERK that does not enter the nucleus at
all, remain undetected in the luciferase assay.
We aimed to determine whether 2-AG release is utilized to a similar extent by
other  Gq-coupled receptors than OX1 to signal to CB1 receptors. Therefore, we
transfected the CHO-hCB1 cells  to  express  human M1 receptors that have also been
reported to utilize endocannabinoids in their signaling (Fukudome et al., 2004). M1
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receptor activation induced similar IP production as activation of OX1 receptors.
Although THL and AM-251 slightly shifted the concentration–response curve of
oxotremorine-M (an M1 agonist) with regard to Elk1 activation and reduced the
maximum response, the effect was significantly smaller than for OX1. OX1 activation
induces strong Ca2+ influx, probably stronger than M1, which could lead to differences
in 2-AG release if DAGL is responsive to Ca2+ elevation.
The cellular background affected the level of potentiation of Elk-1 signaling.
When CHO-hCB1 cells were transfected to co-express OX1, the potentiation was
slightly stronger than when CHO-hOX1 cells were transfected to co-express CB1.
There were also differences in the maximal responses to agonists when the receptors
were expressed in different backgrounds. In CHO-hCB1 cells transfected with cDNA
encoding OX1, the maximal responses to orexin-A and the CB1 agonist HU-210 were
similar. In CHO-hOX1 cells transfected with CB1, on the other hand, the maximal
response to orexin-A was significantly higher than that to HU-210. These differences
could be explained by different expression levels and stoichiometry of the receptors,
and we therefore decided to determine the expression levels of the receptors in these
systems by radioligand binding. Transient expression of CB1 receptors in CHO-hOX1
cells  or  OX1 receptors in CHO-hCB1 cells did not affect the expression levels of
stably expressed OX1 and  CB1 receptors  in  these  cells.  The  expression  level  of
transiently expressed receptors was significantly lower than that of stably expressed
receptors, which is not surprising. The results indicate that the interaction between
OX1 and  CB1 receptors is efficient over a wide range of receptor stoichiometries.
However, it seems that a certain minimum expression level would be needed for each
receptor type. A high enough level of OX1 receptors would be needed to produce
enough 2-AG for any significant stimulation of the CB1 receptor pathway, and there
should be a minimum number of CB1 receptors to produce effective activation of their
signal pathways. On the other hand, at the other ends of expression ranges, the effects
may be physiologically saturating for the other components of the cascade (such as
DAGL or 2-AG transport). It should be noted, however, that the expression levels of
OX1 receptors cannot be reliably assessed by commercial tools, since receptor
quantitation with 125I-orexin-A binding suffers from many limitations (Kukkonen,
2013b).
The results of paper III further supported the view that the 2-AG released upon
OX1 activation can activate neighboring cells, but in addition has an autocrine action
in cells also expressing CB1 receptors. Our results challenge the idea that the
potentiation  of  OX1 signaling  would  require  heteromerization  with  CB1 receptors
(Hilairet et al., 2003; Ellis et al., 2006). A functional interaction between these two
receptors is a more plausible explanation. However, heteromerization of these
receptors could provide more efficient signaling from OX1 receptors to CB1,  as  it
would bring the receptors closer together, and perhaps make the diffusion distance for
released  2-AG  as  short  as  possible.  We  also  showed  that  another  GPCR,  the  M1
muscarinic receptor, did not produce as strong potentiation of ERK signaling as OX1.
This might be due to differences in the ability of these receptors to activate the
production  of  2-AG,  but  this  could  also  reflect  their  different  ability  to  form
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complexes  with  CB1. Further experiments are required to assess the possible role of
receptor-operated Ca2+ influx or other signaling differences among GPCRs in DAGL
(or 2-AG transport) activation.
5.4. The role of Ca2+ in lipid signaling cascades
As described above (2.3.1), OX1 receptors increase the intracellular Ca2+
concentration by various mechanisms. Receptor-operated Ca2+ influx  is  a  central
signaling mechanism for OX1, but the channels responsible for the response and the
signaling mechanisms are largely unknown (2.3.1). In 2010, Turunen et al. made an
interesting finding: MAFP, an AA analog and a general inhibitor of serine hydrolases
acting on AA in glycerophospholipids, such as PLA2, DAGL, and MAGL, was shown
to inhibit the receptor-operated Ca2+ influx in CHO cells (Turunen et al., 2010). In
Paper II, we reassessed this with new pharmacological tools. We observed that PP
produced strong inhibition of Ca2+ responses, while THL had no effect. DAGL does
not appear to be involved in producing Ca2+ responses,  but the Ca2+ influx seems to
besomehow mediated by cPLA2. The action of cPLA2 releases mediators that are able
to induce Ca2+ influx,  such  as  LPC and  AA or  another  fatty  acid,  and  the  mediators
can be further processed by the enzyme cascades. The cPLA2 product causing the
effect in our test system is currently unknown.
Many signaling cascades utilized by OX1 receptors have been shown to be
dependent on extracellular Ca2+ (Lund et al., 2000; Ammoun et al., 2006a; Johansson
et al., 2007; Turunen et al., 2010). We also observed a similar effect for PLD. At an
extracellular Ca2+ concentration of 140 nM, the PLD response (Paper I) was
abolished, similarly to ERK phosphorylation (Ammoun et al., 2006a). The PLC
response is also affected by the extracellular Ca2+ concentration, but to a lesser extent
(Johansson et al., 2007; Putula and Kukkonen, personal communication). The 3H-AA
overflow response to orexin-A is also highly sensitive to extracellular Ca2+ (Turunen
et al.,  2010),  and  thus  both  cPLA2 and DAGL cascades should be abolished upon
removal of extracellular Ca2+. Even though clearly dependent on extracellular Ca2+,
PLD, PLC (Lund et  al., 2000; Johansson et al., 2007), and ERK (Ammoun et al.,
2006a) are only very weakly activated by an ionomycin- or thapsigargin-induced
increase in the intracellular Ca2+ concentration. On the contrary, an increased
intracellular Ca2+ concentration by itself is enough to very strongly stimulate cPLA2
activity (Turunen et al., 2010; Paper II).
These findings can be attacked from several angles. The case for cPLA2 and
DAGL could be easily explained by the fact that they are Ca2+-dependent enzymes
(Clark et al., 1991; Kramer et al., 1991; Bisogno et  al., 2003), and in the cascades
leading to ERK, there are potential Ca2+-sensitive  effectors.  PLC  is  also  Ca2+-
dependent,  but  it  (or  at  least  PLCb) appears to be, when compared to DAGL or
cPLA2, less affected by a reduction in extracellular Ca2+, as also investigated using
the  M1 muscarinic receptor (Johansson et al., 2007). However, PLD or its upstream
activator nPKC should not be Ca2+-sensitive (reviewed in Steinberg, 2004). We have
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observed similar discrepancies for other responses such as AC regulation and ERK
(Holmqvist et al., 2005; Ammoun et al., 2006a). Thus it can be speculated that these
responses to the elevated Ca2+ could be more dependent on the effect of receptor-
mediated Ca2+ influx on orexin receptor itself than on these effectors. Extracellular
Ca2+ might also influence the binding of orexin-A to OX1. Extracellular Ca2+ has been
shown to affect the binding of ligands to the metabotropic glutamate receptor 1α, by
binding to the receptor (Jiang et al., 2014). It has recently been observed that Ca2+ is
indeed required for orexin-A binding to the OX1 receptor (Putula and Kukkonen,
personal communication). However, this cannot entirely explain the effect of removal
of extracellular Ca2+ (and  especially  the  effect  of  blocking  of  Ca2+ influx) on orexin
responses (Putula and Kukkonen, personal communication). It can be hypothesized
that Ca2+ can affect OX1 receptors in multiple ways. It modulates orexin binding,
proximal receptor signaling, and also the downstream effectors. The level of impact
on these stages differs between targets. Altogether, the reduction of extracellular Ca2+
seems to be a blunt instrument to study these processes.
5.5. Heteromerization of OX1, OX2, and CB1 receptors
The idea that heteromerization of OX1 and  CB1 could make their functional
interaction more efficient led us to study their heteromerization. Despite the
limitations of some previous studies, discussed above, the evidence for the
heteromerization of these receptors is rather compelling. This heteromerization and
the trafficking of these complexes has been investigated with for example FRET and
biotinylation methods (Hilairet et al., 2003; Ellis et al., 2006; Ward et al., 2011).
We utilized the BRET method to investigate complex formation between
Rluc- and GFP2-tagged CB1, OX1 and OX2 receptors in CHO cells. BRET has certain
advantages as compared to FRET: while FRET requires excitation with a light source,
which can cause high signal background and even photobleaching, BRET is based on
the  hydrolysis  of  a  substrate  for  luciferase,  and  its  signal-to-noise  ratio  is  therefore
better (reviewed in Salahpour et  al.,  2012).  We  started  by  examining  the  complex
formation between orexin receptors. Both OX1 and OX2 receptors formed constitutive
homomeric but also heteromeric complexes, as revealed by BRET. The BRET ratios
showed  saturation  when  the  amount  of  the  GFP2 construct cDNA was increased in
relation to the Rluc construct cDNA. The saturation implies that the formation of the
complexes was specific. OX2-Rluc-OX1GFP2 showed a strong response and a nicely
saturating  BRET curve,  but  when the  tags  (OX1-Rluc-OX2GFP2) were reversed, the
signal was weaker, and the combination did not produce as good a saturation curve as
the previous one. These differences could be due to the geometry of the complex. It
can be speculated that in some types of complexes, the GFP2 may be more easily
reached by the energy released from Rluc than in some others. We then also tested the
ability of both OX1 and  OX2 receptors  to  form  complexes  with  CB1 receptors. All
receptor  combinations  gave  BRET  signals  and  showed  saturation,  but  we  again
observed differences in the saturation curves similar to the ones described for the
combinations of OX1 and OX2.
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Our BRET results are in line with previous studies (Hilairet et al., 2003; Ellis
et al., 2006; Ward et al., 2011) reporting heteromeric complexes between CB1 and
OX1 receptors. In addition, we demonstrated that human OX2 receptors can also form
constitutive homomers and heteromeric complexes with both OX1 and  CB1. The
ability of mouse OX2 receptor splice variants to from complexes with each other has
also recently been shown (Wang et al., 2013a). Our studies, and the previous ones,
imply that these receptors are capable of forming complexes, which is typical for
many GPCRs. The formation of these receptor complexes has, however, only been
demonstrated  in  recombinant  cells,  and  there  is  no  evidence  for  it  in  physiological
settings. IUPHAR has three criteria of which at least two have to be fulfilled before
dimerization of a certain pair of receptors can be regarded as biologically significant:
1) the dimerization has to be shown in native tissues or primary cells, 2) there has to
be proof of dimer-specific signaling, agonist binding, or bivalent ligands for the
dimer, and 3) the dimerization has to be validated in vivo with, for example, knockout
animals or siRNA (Pin et al., 2007; reviewed in Hiller et al., 2013). However, the
problem with these criteria is that the effects seen in knockout animals, or when using
siRNA techniques recommended for studying multimerization in vivo, could be due to
lack of the absent receptor and not necessarily the lack of multimerization. Therefore,
meeting the third criterion does not necessarily mean that the multimerization is
physiologically relevant. Nevertheless, none of these criteria are met in the case of
CB1 or  OX1 dimers/oligomers, because the changes in the signaling reported by
Hilairet et al. (2003) and Ellis et al. (2006) can be explained by more plausible and
simple functional interactions. While there are no means for inhibiting the complex
formation between these receptors, it is impossible to determine whether the
dimerization affects their signaling by, for example, bringing the CB1 receptors closer
to the highest possible concentrations of 2-AG.
Heteromerization as such is interesting and has been investigated by various
means  and  reported  for  many  GPCRs  (reviewed  in  Hiller et al., 2013). The
heteromerization of receptors can affect their signaling, trafficking, and
pharmacology. For example, bivalent ligands could be used as more efficacious or
selective agonists, or as antagonists for the receptors. There is also evidence for
disease-specific dimerization of receptors, and the development of bivalent ligands
could be especially useful for these types of situations (reviewed in Hiller et al.,
2013).
5.5 Comments on interactions between CB1 and OX1 receptors
Three out of the four papers of this thesis concern interactions between OX1 and CB1
receptors. Other studies have reported evidence of such interactions, but none of them
have  directly  shown  production  and  release  of  2-AG  upon  OX1 stimulation. Our
results reported in Papers II and III demonstrate that OX1 produces potent 2-AG
release, and that this 2-AG can act as a paracrine or autocrine messenger. 2-AG is
known to act in retrograde synaptic transmission, and our findings confirm the view
that OX1 activation can produce this retrograde messenger. The study by Haj-
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Dahmane et al. (2005) provided the first electrophysiological evidence for this in
hypothalamic slices, and another study implicated a similar scheme in the
ventrolateral PAG (Ho et  al., 2011). According to these studies, orexins inhibit the
presynaptic activity of both glutamate and GABA neurons via endocannabinoid
release. Cristino et al. (2013) confirmed that in the lateral hypothalamus, the neurons
that innervate orexin neurons and are thus inhibited by orexin-induced
endocannabinoid release, can be either glutamatergic or GABAergic. In obese mice,
the GABAergic innervation of orexin neurons is dominant (Cristino  et al., 2013).
There is no doubt that this type of functional interaction between OX1 and  CB1
receptors exists. There is also evidence that CB1 receptor mRNA and PPO mRNA are
expressed in the same cells (Cota et al., 2003). However, there is no evidence of both
OX1 and  CB1 receptors being expressed in the same cells. Therefore, although
heteromerization of these receptors now has been convincingly shown, physiological
evidence is lacking. Nevertheless, the concept of heteromerization is interesting, and
in Paper IV we examined it with a new method. Even though it seems more plausible
that the interaction of these systems is functional, it is not impossible that direct
physical receptor interactions could occur.
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6. Conclusions
The studies forming this thesis add to our knowledge of OX1 receptor signaling and
especially the roles of lipid mediators. When compared to other GPCRs, especially
another strongly Gq-coupled receptor, the human M1 muscarinic acetylcholine
receptor, the OX1 receptor may show unique signaling features. However, it may also
be that in recombinant cells the high receptor expression levels distort the signaling.
In our studies, we were able to demonstrate that:
1) OX1 activation of a novel PKC isoform, probably PKCδ, leads to the activation of
PLD1 in CHO cells;
2) OX1 activation leads to copious AA release by the action of cPLA2 in CHO cells.
cPLA2 activity is also required for orexin receptor-operated Ca2+ influx;
3) OX1 activation leads to strong release of the endocannabinoid 2-AG from CHO,
neuro-2a, and HEK293 cells. The production of 2-AG is evoked by a cascade
involving PLC and DAGL activation. The released 2-AG can act in a paracrine or
autocrine manner, and is therefore able to mediate retrograde synaptic transmission.
In addition, 2-AG may act as a source of free AA;
4) Orexin receptor subtypes and CB1 cannabinoid receptors dimerize in any
combination. However, we also demonstrated that the previously reported co-
signaling of OX1 and CB1 receptors, upon co-expression, essentially requires that 2-
AG, elevated by OX1 receptor signaling, acts on CB1 receptors. We therefore believe
that the heterodimerization of the receptor is of lesser importance.
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7. Future perspectives
A novel PKC was previously found to mediate part of the AC stimulation upon OX1
receptor activation in CHO cells (Holmqvist et al., 2005). For both AC and PLD1, the
involved PKC isoform is suggested to be PKCd, although we did not have access to a
very specific inhibitor of this isoform. Recombinant PKCd is translocated to the
plasma membrane in CHO cells upon orexin receptor activation (Holmqvist  et al.,
2005). This is probably driven by PLC-produced DAG, thus constituting a likely
activation route for PKCd activation. The nPKC-dependent component of the AC
stimulation is indeed sensitive to the PLC inhibitor U-73122 (Holmqvist et al., 2005).
However, we did not observe any inhibition of PLD1 activation by this inhibitor,
although we verified its effect in the PLC assay (Paper I). These findings thus stand in
direct contradiction. The tools available constitute one of the problems. U-73122 is
not very specific for PLC, and neither is it very stable. We also attempted to examine
PKCδ phosphorylation upon OX1 stimulation,  but  the  antibodies  we had  at  the  time
did not appear to work, and the project was put on the shelf. Involvement of novel
PKC activation in this signaling is nevertheless very interesting - and also the lack of
involvement of PKCe - and I would like to determine the upstream mediators of
PKCδ activation. Perhaps better antibodies could now be available, or phosphopeptide
analysis  of  PKCd could be performed. PKCd inhibitor peptides could perhaps be
synthesized in-house, and the role of PKCd in orexin receptor responses in other
tissues could be assessed with them.
The physiological importance of the novel lipid pathways of PA (from PLD),
AA  (from  cPLA2 and  DAGL),  and  2-AG  (from  DAGL)  is  one  major  question  that
arises. There have been previous findings of 2-AG-mediated orexin signaling in the
ventrolateral  PAG  and  DR  (2.6). However, how general a mechanism for orexin
receptor signaling is this? Is the role of 2-AG only to act on CB1/2 receptors, or is the
production of AA from 2-AG hydrolysis also of importance for orexin signaling? Are
orexin receptors particularly prone to activating 2-AG production? Are OX1 and CB1
receptors expressed in the same native cells, and is their co-signaling of importance?
We  and  others  (Ellis et al., 2006; Ward et  al.,  2011)  have  shown  that  in
recombinant cells (CHO cells in our case), OX1 and CB1 receptors are indeed able to
form complexes. Complex formation between GPCRs has been shown to affect the
trafficking of the receptors (reviewed in Hiller et al., 2013), and from previous studies
there is some evidence that the cellular localization of OX1 and  CB1 complexes is
affected by their ligands (Ellis et al., 2006; Ward et al., 2011). It would be interesting
to  examine  how  agonists  of  OX1 and  CB1 receptors, and especially the 2-AG
produced upon OX1 activation, affect this. The effect of OX1 activation-induced 2-AG
release on the formation of these complexes is also of great interest. Does the 2-AG
signaling to CB1 perhaps enhance the formation of the CB1-OX1 heteromer?
PLD and cPLA2 responses have thus far only been reported in these
recombinant CHO cells. Both responses are potently activated, but are they of any
significance to orexin physiology? There are rather good pharmacological tools (both
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the ones used here and the subtype-nonselective inhibitor FIPI) to assess these
cascades in native cells, so it should be possible to analyze the responses in, for
instance, native neurons. The cPLA2 cascade, based on the inhibitor used,
pyrrophenone, is important in regulating the orexin receptor-operated Ca2+ influx in
CHO cells (Paper II). This influx was reported more than ten years ago, and the
channel identity and its activation mechanism have been investigated in many
subsequent studies (2.3.1). It would be very interesting to identify which of the many
possible products of the cPLA2 cascade are responsible for the orexin receptor-
operated Ca2+ influx. This might also give a clue to the channel identity. Orexin
receptors are additionally known to activate NSCCs in the brain (2.3.1), and thus
studies in CHO cells could also help to identify the signaling mechanisms in native
neurons.
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